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ABSTRACT
The Impact of Federal Regu)ation on 1ime to F.quivalence
and Comp1~:nce within the Orthopaedic Medicai Device Industry
The Medica! Device Amendments of 1976 (Public Law 94-295) consolidated and expanded
existing federal ~mthority over manufacturers of medical devices. This m:ant that any medical
device manufactured after the Medical Device Amendment of 1976 needed to establish that it is
substantially equivalent in terms of conten~ composition, intended use and related risk. This study
was designed to investigate the influences on the process of notifying the Food ~nd Drug
Administration (FDA) of an orthopaedic medical device manufacturer's intent to market a
product. The study's primary objective;; w~ twofoirl: i) determine the relationships of three
independent variables (i.e., the company's su.e and longevity) with the dependent \tariable, time
to equivalence and 2) compare differences in mean days to equivalen~ based on specified
company characteristics (i.e., regulatory affairs consultant use, regulatory training experiences,
in-house regulatory department presence or absence, and attitudes toward influences on timely
compliance). A survey instrument was returned by the regulatory manager at 39 companies
representing 263 device equivalen~ submissions and 27 different medical device categories from
1977 through 1987. Four different statistical approaches were utilized: correlative-regressive,
comparative, regressive-predictive, and distributive. From ilibi research certain company
characteristics which impact time to equivalence were identified. It was found that companies who
have been manufacturing numerous years, manufacture more than one medical device, and use
regulatory affairs professionals to assist with compliance issues, especially just following the
e-uactment of a new regulation, may have predictaNv fewer days to equivalence than companies
that do not possess these characteristics. Statistically significant relationships and differences in
mean days to equivalence were computed for some variables.
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Time To Equiva lence
CHAPTER I

INTR0:i::D'CTION

What do Band-A ids, contac t lenses , cardia c pacem akers, and
magne tic resona nce imagin g machin es have in common? They are all
medica l device s, accord ing to federa l law. Judgin g the safety and
effect ivenes s of these four produ cts and over 47,000 other medic al
device s is the job of the Food and Drug Admin istrati on (FDA). But
for a variet y of reason s, federa l regula tion of medic al device s is
beset with major proble ms. As a result , little inform ation is
availa ble to determ ine wheth er medic al device s, which are becom ing
increa singly sophi sticat ed, are safe and work as intend ed.
The situat ion above has forced the FDA~~ revers e ths presen t
congre ssiona l sentim ent of deregu lation and, conseq uently , impose
more contro ls upon medic al device manuf acture rs. The numbe r of
device establ ishme nts has explod ed to more than 12,000 and every
one is jockey ing for marke t positi on. Govern ment requir ement s are
a hurdle to new produ cts and better sales.
Thie

study

propos es

to

evalua te

the

relatio nship s

and

differ ences betwee n regula tory requir ement s and time to establ ished
equiva lence or FDA dispo sition in the orthop aedic medic al device
indust ry. The conce ntratio n in the orthop aedic area in the medic al
device indust ry was guided by concer ns regard ing the narrow ing of
Page 1
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researc h focus and signifi cance of ultimat e researc h finding s. More
specifi cally, the process of interpr eting regulat ory require ments
and timely submis sions in the orthopa edic medica l device area is
the primary aim of this researc h. The paradig m, •Time is money! ",
is sssant ially being examine d.

remains

off the market ,

The longer a develop ed produc t

the greater the consum ption of the

manufa cturer's resourc es and decreas ed share of market .
The degree of market share protect ion a company can expect
depends on the rouce chosen by the company to market its produc t.
One route is the section 510(k) (Public Law No. 94-295 ), or the
premar ket notific ation process (PMAA), of the Federa l Food, Drug,
and Cosmet ic Act (FDC Act) (Public Law No. 75-717 ). Under section
Sl0(k), a manufa cturer is require d to file with FDA a premar ket
notific ation at least ninety days before market ing a class I or
class I I device. The purpose of the 510(k) is to establi sh that the
device is substa ntially equiva lent to another device already on the
market . A 510(k) notific ation is genera lly a few pages long and
usually does not contain clinica l data. The FDA's average review
time for the Sl0(k) is approxi mately 64 days (FDA Annual Report ,
1988). Althoug h FDA has 90 days to comple te the review proces s, the
manufa cturer must wait for either 90 days or until it is notifie d
by FDA of the device 's equival ence.
The PMAA process is the second route to market . The conten t
require ments for a PMAA are much more rigorou s than the
Page 2
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requir ement s for the SlO(k) notifi cation proces s. A PMAA is a
volumi nous and detail ed submi ssion that usuall y includ es
precli nical and clinic al data. The averag e review time for a PMAA
is 142 to 262 days (FDA Annua l Repor t, 1988).
The scope of this resear ch is limite d to gather ing data as it
relate s to the SlO(k) proces s only.
The SlOlK) Regis ter (Dioge nes, 1988) is a docum ent which has
been publis hed annua lly since 1976. This is the year in which
regula tory reform was introd uced to the medic al device indust ry.
All SlO(k) s filed since 1976 are listed in this docum ent. From this
text can be gleane d the submi ssion dates and the dates when
equiva lence was determ ined. These days c~n v~r:-i from as few as two
days to as many as 200 or more. Estima ted costs are associ ated with
each day that produ ct does not reach equiva lence and ultima tely the
marke t. These days are reduce d or enhanc ed by the manuf acture r's
abilit y to interp ret regula tions, comply with those regula tions,
and establ ish substa ntial equiva lence to a produc t which was on the
marke t prior to 1976.

THE

PROBLEM

Statem ent of Proble m
The Medic al Device Amendments of 1976 (Publi c Law 94-295 )
conso lidated and expand ed existi ng federa l autho rity over medic al
device s. It enacte d a system of regula ting safety and effect ivenes s
Page 3
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of medica l devices in propor tio~ to the degree of risk they posed.
This meant that any medica l device manufa ctured after the Medica l
Device .Amendment of 1976 needed to establi sh that it was
substa ntially equiva lent in terms of conten t, compos ition, intende d
use and related risk. If this equival ency was establi shed, FDA
require d nothing more than pre-ma rket notific ation. If found not
to be equiva lent; other more rigorou s require ments were imposed
(e.g., multi-c entered clinica l trials) . Conduc ting multi-c entered
clinica l trials was very expensi ve and resourc e intensi ve. Even if
equival ence could be e&·c.db lished, delays, due to misint erpreta tion
of guideli nes, inabili ty to provide =equire d inform ation, etc., in
securin g the FDA's dispos ition could also incur additio nal
expens es.
The task of i.mplem enting some of the key provisi ons and
managin g the cost of some provisi ons relativ e to the increm ental
gains in safety and effecti veness have placed conside rable burdens
on the medica l device industr y. Regard less of efforts by FDA to
stream line the approv al process , Drew (1986) emphas ized that many
of the large firms and a majori ty of the small firms were at the
leading edge of science and technol ogy, but had relativ ely little
knowled ge and experie nce in meeting regulat ory require ments. This
situati on might only slightl y delay the market ing of a produc t or
might result, in the most extreme case, in the demise of an
organiz ation. The purpose of this study was to assess the impact
Page 4
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of regula tory compl iance on time to equiva lence in the orthop aedic
medic al device indust ry.
The data gather ed regard ing the depend ent variab le, time to
equiva lence (days) and produ ct chara cteris tics was obtain ed from
a docum ent refere nced in the Introd uction sectio n of this paper,
The Sl0Ck) Regis ter. This annua lly publis hed docum ent provid ed the
follow ing inform ation: produc t classi ficati on, produ ct type,
sponso r or manuf acture r's name,

submi ssion date,

and date of

substa ntial equiva lence. It also listed the numbe r of reque sts by
FDA for furthe r inform ation before dispo sition was reache d, and
elapse d days from time of sci:>m ission to time of equiva lence.
The predic ~or or indepe ndent variab les, X, were: numbe r of
years manuf acturin g medic al device s, organ izatio nal size, and
regula tory depart ment size, if presen t.
One-wa y analys is of varian ce was perfor med to assess the
differ ence in organ izatio nal chara cteris tics and time to
equiva lence. The criter ion or depend ent variab le was measu red in
tinie (days) to equiva lence.
The
ordina l

indepe ndent variab les
levels

of

measu rement .

were

discre te

Those

dichot omies

variab les

includ ed

and
the

follow ing: the type of medic al device manuf a~ture d, the presen ce
or absenc e of an in-hou se regula tory depart ment, regula tory
traini ng experi ence, numbe r of medic al device s manuf acture d, use
of out-of -house regula tory consu ltants , attitu de toward writte n
Page 5
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commu nicatio n with FDA, attitu de toward oral commu nicatio n with
FDA, attitu de toward regula tory traini ng, attitu. de toward the
presen ce of an in-hou se regula tory depart ment, attitu de toward the
use of out-of -house regula tory consu ltants , and produ ction costs.
As indica ted above, Resear ch Questi on Number 2 and Hypoth eses

2.1 listed below entail ed evalua tion of the type of medic al device
manuf acture d. This classi ficati on scheme develo ped by FDA was
explic ated in the Defin itions sectio n of this docum ent. A device
was classi fied as class I, II, or III based upon the degree of risk
regard ing

safety

compl exity.

and

effect ivenes s

of

the

device

Orthop aedic dsvice classi ficati on I

and

its

would includ e

simple device types which pose minim al risk to the patien t (e.g.,
bandag e, cast, forcep s, etc.). Class ificat ion III would includ e
device s which presen t a

signif icant risk,

such as,

should er

prosth esis or arti!i cial heart.
Furthe r analys is entail ed the invest igatio n of the combin ed
influe nce of indepe ndent variab les which best predic ted time to
equiva lence.
All analys es were strati fied by the ~ears 1977 throug h 1987.
If distri bution imbala nces we~e observ ed, nonpa rametr ic tools
were impose d.
Progn ostic

inform ation

was

questi onnai res, phone interv iews,

retrie ved

via

mailed

and person al interv iews • 'l'he

questi onnair e enclos ed in Appen dix C served as the data collec tion
Page 6
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vehic le.
~ll hypot heses were state d in the null.
Ultim ately, this study was desig ned to inves tigate the
influe nces on the proce ss of notif ying FDA of an ortho paedi
c
medic al devic e manu factu rer's inten t to marke t a produ ct which
was
subst antia lly equiv alent to a devic e manu factuz ed prior to the
1976
Medic al Devic e Amen dment s.
Resea rch Quest ions
Resea rch Quest ion Number 1
What is the relati onsh ip betwe en time devot ed to estab lishin
g
an FDA dispo sition of subst antia l equiv alenc e for an ortho paedi
c
medic al devic e and relate d costs and resou rce consu mptio n?
Hypo thesis 1.1. There is no relati onsh ip betwe en time (days
)
neede d to estab lish equiv alenc e and the numbe r of years
a
compa ny has been manu factur ing medic al devic es. This
hypot hesis relat es to quest ion numbe= 1 en ths quest ionna ire.
Hypo thesis 1.2. There is no relati onsh ip betwe en time (days
)
neede d to estab lish equiv alenc e and the numbe r of emplo yees
in an organ izatio n. This hypot hesis relat es to quest ion numbe
r
2 on the quest ionna ire
Hypo thesis 1.3. There is no relati onsh ip betwe eu time (days
)
neede d to estab lish equiv alenc e and the numbe r of emplo yees
in the regul atory depar tment .

This hypot hesis relat es to

quest ion numbe r 2 on the quest ionna ire.
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Resear ch Questi on Number 2
Is there any differ ence betwee n xespon dentd (comp anies) who
posses s or do not posses s certai n identi fied chara cteris tics and
time requir ed to establ ish equiva lence?
Hypot hesis 2.1. There is no differ ence betwee n the type of
medic al device manuf acture d and time to equiva lence. This
hypoth esis relate s to inform ation secure d from The 510 Ck)
Regis ter.
Hypot hesis 2 . 2 • There is no di£ f erence betwee n
having in-hou se regula tory depart ments
don't

have

in-hou se

regula tory

compa nies

and compa nies that

depart ments

on

time

to

equiva lence. This hypoth ~sis relate s to questi on numbe r 2 on
the questi onnai re.
Hypot hesis 2.3. There is no differ ence betwee n compa nies who
receiv ed regula tory compl iance traini ng and compa nies who
didn't receiv e regula tory compl iance traini ng on time to
equiva lence. This hypoth esis relat~ s to questi on numbe r 3 on
the questi onnair e.
Hypot hesis 2.4. There is no differ ence betwee n compa nies who
manuf acture one medic al device and compa nies that manuf acture
more than one device on time to equiva lence. This hypoth esis
relate s to questi on numbe r 3 on the questi onnai re.
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Hypo thesis 2. 5. There is no diffe rence betwe en compa nies who
repor t using regul atory affai rs consu ltants and compa nies that
don't use regul atory affai rs consu ltants on time to
equiv alenc e. ~his hypot hesis relat es to quest ion numbe r 2 on
the quest ionna ire.

Resea rch Quest ion Number 3
Is there any differ ence betwe en time to equiv alenc e and
respo ndent 's (comp any's) attitu des about selec ted chara cteri
stics
of

the

regul atory

proce ss

as

havin g

an

impac t

on

time

to

equiv alenc e?

Hypo thesis 3.1. There is no differ ence betwe en the compa nies
who perce ive FDA writt en comm unicat ion as havin g an impac t on
timel y comp liance and compa nies that don't perce ive FDA
writt en comm unicat ion as havin g an impac t on timel y comp liance
on time to equiv alenc e. This hypot hesis relat es to quest ion
numbe r 5 on the quest ionna ire.
Hypo thesis 3.2. There is no differ ence betwe en compa nies who
perce ive FDA oral comm unicat ion as havin g an impac t on timel
y
comp liance and compa nies that don't perce ive FDA oral
comm unicat iQP. as havin g an impac t on timel y comp liance on time
to equiv alenc e. This hypot hesis relat es to quest ion numbe r
6
on the quest ionna ire.
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Hypo thesis 3.3. There is no diffe rence betwe en compa nies who
perce ive the Offic e of Small Manu factur ers Assis tance (OSMA)
regula tor:1r comp liance train ing as havin g an impac t on timel y
comp liance and compa nies who don't perce ive the OSMA
regul atory comp liance train ing as havin g an impac t on timel y
comp liance on time to equiv alenc e. This hypot hesis relat es to
quest ion numbe r 7 on the quest ionna ire.
Hypo thesis 3.4. There is no diffe rence betwe en compa nies who
perce ive havin g an in-ho use regul atory depar tment as havin g
an impac t on timel y comp liance and compa nies who don't
perce ive havin g an in-ho use regul atory depar tment as havin g
an impac t on timel y comp liance on time to equiv alenc e. This
hypot hesis relat es to quest ion numbe r 8 on the quest ionna ire.
Hypo thesis 3.5. There is no diffe rence betwe en compa nies who
perce ive the use of outsi de regul atory affai rs consu ltants as
havin g an impac t on timel y comp liance and compa nies that don't
perce ive the use of outsi de regul atory affai rs consu ltants as
havin g an impac t on timel y comp liance on time to equiv alenc e.
This hypot hesis relat es to quest ion numbe r 9 on the
quest ionna ire
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Resear ch Questi on Number 4
What
predic ts

combi nation
time

to

of

indepe ndent

eq-uiv alence ?

This

variab le
resear ch

mea~u res
questi on

best
takes

inform ation from all the questi ons on the questi onnai re.
Resear ch Questi on Number 5
What variab les appear to have an impact on time to equiva lence
as percei ved by the compan y respon dent? This resear ch questi on
relate s to questi ons numbe r 4 and 10 on the qu~at ionnai re.
Import ance and Releva nce
Numerous change s in FDA regula tions over the past ten years
have create d a dynam ic enviro nment for firms in the medic al device
indust ry. Al though the overa ll pictur e for the medic al device
indust ry was optim istic and growin g, the reperc ussion s of the 1976
legisl ation presen ted seriou s proble ms. Cost of compl iance, FDA
expec tation s, FDA dispo sition s, and device reclas sifica tions all
placed a strain on indivi dual firm resour ces and manag ement. Any
effort to conser ve resour ces and reduce costs while mainta ining
marke t positi on was viewed as cost effect ive and benef icial to
manage ment in medic al device enterp rises.
Speci fically , compl iance with federa l regula tions and relate d
strate gic adapta tion in relati on to resour ce alloca tion and cost
reduct ion in the medic al device indust ry had not been direct ly
Page 11
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investi gated

in

the

past.

Financ ial

surviva l

and

industr y

leaders hip may directl y be linked with regulat ory complia nce. Of
importa nce might be the investi gation of the relatio nship between
regulat ory dispos itions and medica l device corpor ate short/l ong
term plannin g in respons e to regulat ory agencie s require ments. Does
a pattern exist in which predict able elemen ts emerge which, with
some high probab ility, contrib ute to reduced days in securin g FDA
dispos ition (equiva lence) regardi ng a produc t?
It would be of value if a manage r could anticip ate with some
reliab ility the approxi mate number of days it would take for that
produc t tc reach equival ence once a Sl0(k) had been submit ted to
FDA. With this knowled ge there could be some plannin g alterat ions
in terms of market ing, sales, and produc tion strateg ies.
Assumin g the federal social regulat ions inheren t in the FDA
guideli nes were in accorda nce with the degree of risk associa ted
with the device and that these guideli nes did provide an adequa te
audit trail which, if followe d, were cost accoun table at the very
least, the regulat ory departm ent manage r or corresp onding
respon sible individ ual could and should benefi t from being well
versed in the avenues essent ial to reachin g equiva lence.
One of the major decisio ns related to the cost of the
equival ence process was the use of in-hous e versus out-of- house
regulat ory profess ionals.
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Managem ent must
determ ine

when

it

be

was

able
cost

to

weigh

effecti ve

certain variabl es
to

bring

in

to

outside

consul tants to assist in the interpr etation of device related
guideli nes. There were multip le factors for the chief executi ve to
take into accoun t when conside ring whethe r to use in-hous e or
outside regulat ory profess ionals. When evalua ting availab le
resourc es and possib le costs in establi shing equival ence not only
on one device at one point in time, but equival ence for numerou s
devices over years, a chief executi ve might conside r the followi ng
possib ilities: expand ing the respon sibiliti es of presen t employ ees,
develop ing a new departm ent (Regula tory Affair s), and/or hiring
more employ ees for the new departm ent. If a regulat ory departm ent
was already in-hous e, the chief executi ve may need to hire more
employ ees to meet the increas ed demand s, or enlist the assista nce
of regulat ory consul tants outside of the firm. This study evaluat ed
the above implied variab les and associa ted pattern s.

Researc h Assump tions and Limita tions
To gain a greater underst anding of the limitat ions of this
researc h, it was necess~ .i'
extend the review to key
method ologica l charac teristic s. In order to do so, three aspects
of

the

researc h design were

examine d

-

1)

data

source,

2)

measure ment of profita bility, and 3) data analys is.
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The different types of measureme nt procedures employed in
operation alizing a construct played a critical role in determinin g
the validity of the results.
analysis,

quantitati ve

These

calculatio n,

procedures

(e.g., content

investigat or

inference)

translated data sources (e.g., questionn aire, publicly available

510lk)

Register)

into

specific

types

of

measures

(e.g.,

retrospect ive nominal and ordinal scales, trend lines).
Data

analysis

referred to whether the type of anclysis

employed was qualitativ e or quantitati ve. This character istic was
important for differenti ating findings which were primarily useful
for theory building from those which were useful to theory testing.
Methodolo gical Tradeoffs
Miller and Friesen (1982) in reviewing the character istics of
different approaches to longitudin al analysis of orga~izati ons,
identified three major dimensions along which research t~adeoffs
were

generally made:

1)

breadth

of

focus,

i.e.,

number

of

variables, 2) sample size and 3) the extent to which quantifica tion
occurs. Relative ease in analy~is and interpreta tion were generally

achieved at the exp~nse of specificat ion error created by an overly
narrow scope, lack of generali~ ability created by overly small
sample size, or lack of reliabilit y due to a non-quant itative
analysis approach.
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These shortcomin gs in turn lead to a body of non-cumul ative
findings.

On the other hand,

achieved at

the

expense of

cumulative
a

lack of

findings were often
appropriat e

data

and

inadequate model constructi on due to quest for overly broad scope.
Data collection tended to be inefficien t and over-gene ralization
tended to occur because of an overly large sample size and overdependence on quantitati ve analysis that ignored the importance of
intuition- guiding 'soft data'.
In addition, the existence of nonlinea~ ities and intrasampl e
difference s tended to be overlooked . All of these problems lead to
findings that were cumulative , but difficult to interpret.
The above highlighte d precaution s and concerns bring about the
following research assumption s and delimitati ons:

Assumption s
1.

Federal social regulation did impact time to equivalenc e

and related financial profits in orthopaedi c medical device firms
to a varying degree.
2.

The impact of federal social regulation upon time to

equivalenc e could be perceived by top managemen t

(Regulator y

Affairs Departmen t Director) of medical device firms.
3.

The

sampled population was

fairly

homogeneou s

when

stratified by calendar year.
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4.

Prof it-m akin g was

esse ntia l

to

the

purp ose

of

any

busi ness in the Unit ed Stat es.
5.

Resp onde nts

indi vidu als

as

to

to

the

impa cts

of

ques tion nair e
regu latio ns

and

were

infor med

orga niza tion al

char acte risti cs.
6.

The rese arch desi gn was adeq uate for the purp ose
of the

7.

The

anal ysis

of

data

did

not

sign ifica ntly

alte r

rela tion ship s among vari able s and gave an adeq uate
repr esen tatio n
of rela tion ship s.
8.

The data coll ecte d were a satis fact ory indi catio
n of the
impa ct of fede ral soci al regu latio n upon time to
equi vale nce for
orth opae dic med ical devi ce man ufac turer s.

Deli mita tions
The ques tion nair e was dist ribu ted to top- leve l exec
utive s
of rand omiz ed orth opae dic med ical devi ce firm
s thro ugho ut the
Unit ed Stat es.
1.

2.

The

rese arch

was

limi ted

to

info rmat ion

will ingl y

supp lied by part icip ant firm s.
The meas urem ent of time to equi vale nce and
rela ted
prof itab ility in the orth opae dic med ical devi ce field
as it rela tes
to fede ral regu latio n was a rela tive ly new ende
avor . Conc lusio ns
base d upon find ings of the stud y shou ld not
be cons idere d
3.
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appropriat e

for

generaliza tion

to

areas

other

than

those

encompasse d by the present study.
4.

The role of the researcher was to evaluate the influences

of a regulatory process, as well as, determine the dynamics of
emergence in the orthopaedi c medical dev~ce industry. These two
motives for exploratio n could have introduced some conflicts and
bias.

Definition s
Corporate Social Responsib ility: This term referred to compliance
measures implemente d by a corporatio n which could alter or adjust
product

design,

distributi on

in

developme nt;
response

to

manufactu ring,
health

and

procureme nt,

safety

or

requiremen ts

stipulated through federal social regulation .
Pre-amendm ent Devices: Devices on the market before May 28, 1976,
when the Medical Device Amendments were enacted.
Post-amend ment Devices: Devices put on the market after May 28,
1976. Unless shown to be substantia lly equivalen t to a device that
was on the market before the amendments took effect, these devices
are automatica lly placed in Class III. A manufactu rer may petition
FDA for reclassifi cation.
Substantia l Equivalenc e: Although not defined by law, congressio nal
intent was to ensure fair treatment of post-amend ment devices that
were similar to :pre-amendm ent devices, as well as limit the number
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of new devices that would require premarke ting approval .
SlOlk)

Process:

These

notifica tions

were

the

formal

notices

submitte d to FDA by the medical device industry in order to quickly
obtain FDA permissi on to market medical devices.
Time to Equivale nce:

This defined the time measured in days

required

come

by

FDA

to

a

disposit ion

that

a

device

is

substan tially equivale nt to an already approved device or to a
device marketed prior to May 28, 1976.
Class I Medical Device: Class I, general controls , encompas ses
devices for which general controls were sufficie nt to provide

reasonab le assuranc es of safety and effectiv eness, i.~:. tong-ue
depresso r.
Class II Medical Device: Class II, performa nce standard s, containe d
devices for which controls were consider ed insuffic ient to ensure
safety and effectiv eness and informat ion existed to establis h
performa nce standard s, i.e. X-ray devices.
Class III Medical Device: Class III, premarke t approval , applied
to devices for which general controls were insuffic ient to ensure
safety and efficacy .

Informat ion did not

exist

to estcmlis h

performa nce standard s and the device supports life, prevents heal th
impairme nt, or presents a potentia lly unreason able risk of illness
or injury, i.e. implanta ble heart valve.
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Office of Small Manufa cturers Assista nce COSMA) - This office was
include d in the 1976 enactm ent of the Medica l Device Amendments to
the Food, Drug, and Cosmet ic Act. This legisla tion provide d for the
establis hment of an identif iable office to help small manufa cturers
of

medica l

devices

underst and

and

comply with

the

new FDA

require ments for these produc ts under that law.

Swmnary
Regula tion of orthopa edic medica l device manufa cturers was of
two basic types: ( 1) econom ic regulat ion aimed at maximi zing
profits and (2) social regulat ion aimed at accomp lishing social
objecti ves. Both types affecte d compan ies who manufa cture medica l
devices to a varying degree.
Researc h
differe nces

was

conduc ted

between

charac teristic s,

federal

and time

to

to

determi ne
social

relatio nships

regula tion,

equival ence.

Researc h

and

company
questio ns

examin ing the impact of federal social regulat ion upon time to
equival ence for orthopa edic medica l device manufa cturing firms were
stated.
Deline ation

of

questio ns

separat ed

depend ent

variab les,

indepen dent variab les, and their elemen ts • Genera l linear model and
analys is of varianc e approac hes were used as the researc h method .
Criteri a for data sources were outline d and definit ions of specifi c
terms as used in the study were discuss ed in this chapte r.
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CHAPTER II

REVIEW OF LITERATURE

This sectio n presen ted a review of the litera ture coveri ng
aspect s of social regula tion and the medic al device indus try. An
histor ical dimen sion was presen ted on the interr elatio nship betwee n
govern ment policy and the operat ion of busine ss firms. This sectio n
conclu ded with an overvi ew of govern ment regula tion of medic al
device s by the Food and Drug Admin istrati on.

Histo rical Dimen sion
Social Regul ation
Social regula tions have underg one the greate st growth in terms
of agenci es and expen diture of govern ment funds. weiden baum (1977)
identi fied major expan sion in six areas:

job safety ,

traffi c

safety , consum er produ ct, person nel practi ce and discri minat ion in
employ ment, consum er financ e, enviro nment and resour ces. The growth
of social regula tion has contin ued extens ively. From the period of
1970 to 1977, the numbe r of social regula tory agenci es increa sed
from 12 to 17, and expen diture s for these agenci es rose from
$1,449 .3 millio n to $7,318 .3 millio n (Mille r and Yandle , 1979).
In the area of job safety , federa l and state govern ments have
passed laws affect ing nonun ion worke rs. Includ ed is unemp loymen t
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compen sation, minimum wage laws, social securit y ~~ws, and safety
laws. The Occupa tional Safety and Health Act (OSHA) of 1970 gave
the federal governm ent a tremend ous amount of power and author ity
to set and enforce safety regulat ions even in the smalle st of firms
(Nichol son, Litsch ert, and Anthony , 1974).
In the

area of

traffic

safety,

the NHTSA has

activel y

regulat erl eafety standar ds affecti ng the design of automo biles. For
example , regulat ed safety standar ds include "unifor m bumper
heights , damage limitat ions resulti ng from 5 mph test crashes , and
mandato ry seat belts, air bags, or other restrai nt :mechan isms"
(Ferrei ra, 1982).
In the area of consum er produc ts, fedezal regulat ory interes t
in produc t safety- related matters has grown enormo usly. Severa l new
agencie s with interes ts in produc t safety have been establi shed,
includi ng the Consum er Produc t Safety Connnis sion (CPSC) in 1972.
The Consum er Produc t Safety Act require d the mainten ance of records
to ensure that firms are comply ing with its provisi ons and granted
the CPSC access to these records (Eads, 1981).
A

number

of

preexis ting

agencie s

with

produc t

safety

respon sibiliti es were strengt hened. Among those are the Federa l
Trade Connnis sion (FTC), the Food and Drug Admin istratio n (FDA), and
the Departm ent of Agricu lture (USDA).
In the area of personn el practic e,
Opport unity Connnis sion (EEOC)

the Equal Employm ent

and OSHA have impacte d busines s
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consid erably .

An

idea

propos ed

by

Smith

(1981)

that

would

substi tute for OSHA regula tions would be a $500 deduc tible for
every succe ssful worke r's compe nsation claim.!' with that deduc tible
·then paid by the employ er. This idea did not includ e health
co.-'=!rage.
In +lie area

er

consum er financ e,

federa l credit progra ms

assume d three forms: direct lendin g by United State 's govern mentowned agenc ies, direct lendin g by privat ely owned agenc ies
sponso r.ad by the federa l govern ment to serve public intere st, and
the insuri ng or guaran teeing of loans extend ed direct ly by privat e
lender s
functi on

to
of

privat e
federa l

borrow ers
credit

(Swans on,
agenci es

1974).

was

to

The

immed iate

provid e

credi t

accomm odation for borrow ers gener ally consid ered margin al or at
least subjec t to relati vely high risk arisin g from cyclic al
fluctu ations or other specia l factor s. In a more fundam ental sense,
as Swanso n ( 1974) put it, these agenci es were orient ed toward
redist ributi ng econom ic resour ces for achiev ing greate r econom ic
stabil ity in certai n sector s of the econom y.
In the area of enviro nment al progra ms,

the Enviro nment al

Protec tion ~gency (EPA) contri buted greatl y. The EPA set emissi ons
standa rds for power plants based upon the locati on of each plant,
curren t ambien t conce ntratio ns of air pollut ants, a compu ter model
for the plant 's impact upon local air qualit y, and a consid eratio n
of the techno logy availa ble for contro lling the pollut ants (Barda ch
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and Kagan, 1982). Other regulat ory program s, such as the Clean Air
Act of 1970, disting uished between old and new facilit ies and
placed less stringe nt contro ls upon existin g plants. Under the Act
and its amendm ent of 1977, all cars sold in the United States must
eventu ally achieve a 9 0 percen t reducti on in carbon monoxi de,
hydroca rbons, and nitrous oxide emissio ns from the level of 1970
control s (Bardac h and Kagan, 1982).

Social Regula tion and the Medica l Device Industr y
Medica l device regulat ion was first adhered in the Federa l
Food, Drug, and Cosmet ics Act of 1938. Althoug h this act is best
known for requiri ng pre-ma rket notific ation for the safety of new
drugs, devices also came under its expans ive umbrel la. The 1938 Act
defined medica l devices in the Federa l Registe r as:
•••• instrum ents, appara tus, and contriv ances, includi ng
their compon ents, parts and access ories, intende d ( 1) for
use in the diagno sis, care, mitiga tion, treatme nt, or
preven tion of disease in man or other animals ; or (2) to
affect the structu re or any functio n of the body of man
or other animals .

'!'he 1938 act authori zed FDA to inspec t any site in which
devices were manufa ctured, process ed packed , or held. It also
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authorized FDA to seize adulterated or misbranded medical devices.
FDA also had the power to request an injunction against their
productioni distribution, or use; or seek criminal prosecution of
the responsible manufacturer or distributor. But the agency could
not take action until after a device had been marketed.
In the early regulatory actions taken against adulterated or
misbranded devices, FDA was able to use expert testimony to prove
its allegations. Over time, however, FDA increasingly had to test
devices suspected of violating the law in order to remove these
devices from the market (U.S. Congress House Report No. 94-853).
As medical devices became more complex.after World War II,

attention turned to the regulation of legitimate devices as well.
But FDA could still act only after devices were distributed and
also

had

the

burden of

proving

that

a

particular

item was

misbranded or unsafe, because devices were not subject to premarket
approval (AMP, Inc. v. Gardner, 1968).
In the late 1960 8 ,

however, the courts ruled that certain

products ( such as nylon sutures and antibiotic-sensitive discs)
that fell in the grey area between drugs and devices could legally
be considered drugs and subject to premarket approval requirements
for new drugs (12,302). Subsequently, FDA regulated as "new drugs"
such products as some intrauterine devices (IUDs), some contact
lenses, and some in vitro diagnostic products.
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Furtherm ore, during the late 19 6 0 's, Congress addresse d public
health problems associat ed with radiatio n emission s from electron ic
products . Under the Radiatio n Control for Health and Safety Act of
1968 (Public Law 90-602), Congress establis hed a radiatio n control
program to authoriz e the establish ment of standard s for electron ic
products , includin g medical and dental radiolog y equipme nt.
From the early 1960's to 1975, six Presiden tial messages were
given and

28

bills were

introduc ed to

enact medical

device

legislat ion.
A 1969 Depa....--...:ment of Health, Educatio n, and Welfare review of
the scientif ic literatu re for injuries associat ed with medical
devices that was conducte d by the Cooper Committe e (named after its
chairman , Theodore Cooper, then Director of the National Heart,
Lung, and Blood Institut e of the National Institut es of Health)
estimate d

that

over

a

10-year period,

10,000

injuries

were

associat ed with medical devices, of which 731 resulted in death
(U.S. Congress House Committe e Hearing No. 93-61).
The vast majority of these problems were associat ed with three
device types: artifici al heart valves, 512 deaths and 300 injuries ;
cardiac pacemak ers, 89 deaths and 186 injuries ; and intraute rine
contrace ptive devices, 10 deaths and 8,000 injuries (U.S. Congress
House Committe e Hearing No. 93-61). As observer s noted, however,
there had been no sensatio nal event or public tragedy to spur more
stringen t regulati on of medical devices such as the events leading
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to the 1962 Drug Amendment (Igel hart, 1973) .
Addit ional examp les of hazar ds assoc iated with medic al devic es
were documen.ted in congr essio nal heari ngs in 1973. These inclu
ded
prost hetic and ortho paedi c impla nts of impro per mate rials, cardi
ac
defib rillat ors with fault y elect rical circu itry, incub ators
in
which tempe rature s reach ed as high as 145° F, plast ic trache
otomy
tubes with obstr uctio ns, and fault y valve s on emerg ency
oxyge n
respi rator s (U.S. Congr ess House Comm ittee Heari ng No. 93-61
).
The devel opme nts just descr ibed event ually culmi nated in the
enactm ent of the Medic al Devic e Amendm~nts of lS76 (Publ ic Law
94295).

Today , while publi c well- being and fraud ulent "mira cle cures
"
contin ue to demand FDA's atten tion, it is the numbe r and diver
sity
of legiti mate medic al devic es that prese nt the great est proble
ms
in regul ation . There are more than 1,700 types of medic al de~ic
es;
the vario us model s and sizes of each type add up to betwe en
40,00

0

and 50,00 0 separ ate produ cts (Drew , 1986) . These types of de,.ric
es
range from the simpl est (such as tongu e depre ssors ) to the
most
compl ex (such as magn etic reson ance image rs), and from the
most
routin e (such as urine colle ction bottl es) to the most criti
cal
and life-p reser ving (such as artif icial heart s).
These medic al devic es were produ ced by appro ximat ely 8,000
firms , many of them small , relat ively new enter prise s (Drew , 1986)
.

Over 95 perce nt had fewer than 500 emplo yees, and half of those
had
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fewer than 50 emplo yees.
Many of these small firms were at the leadi ng edge of scien ce
and techn ology , but had relat ively little knowl edge and exper
ience
in meeti ng regul atory requi remen ts. Becau se those requi remen
ts
depen ded on the natur e of the devic e, rathe r than the size of
the
company produ cing it, small firms had to spend a large propo
rtion
of their resou rces for regul atory comp liance than large r firms
.
Recog nizing this situa tion, FDA estab lishe d th~ Divis ion of
Small Manu factur ers Assis tance (DSMA) to help small firms to
cope
with the regul ation s.
All medic al devic es were subje ct to some level of regul ation
by FDA, but the natur e and the degre e of that regul ation varie
s.
The more hazar dous the devic e, the great er the regul ation
. The
inten t was to prote ct users and patie nts, while impos ing the
least
possi ble regul atory burde n on produ cers of devic es.
This ~=s accom plishe d by class ifyin g medic al devic es into
three group s --- Class I, Class II! Class III --- with the
least
hazar dous devic es in Class I and the most hazar dous in Class
III.
The

class ifica tion

of

a

devic e

determ ined

which

regul atory

•chan nel" it follow s.
Class I devic es, such as adhes ive banda ges, tooth brush es and
tongu e depre ssors , prese nt risks that can be manag ed"by "gene
ral
contr ols•.

These

gen~r al

contr ols

repre sente d

a

regul atory

basel ine, which all manu factu rers, impo rters, and distri butor
s must
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meet. They include d registr ation of the firm with FDA and period ic
listing of all medica l devices produce d or handled by the firm.
Also, whenev er a firm intende d to introdu ce a new or signifi cantly
modifie d device to its produc t line, it had to notify FDA at least
90 days before market ing the device.
Other genera l contro ls include d adequa te labelin g and good
manufa cturing practic es in produc ing devices . Drew (1986) reporte d
460 types of Class I medica l device s, 27 percen t of the total
number of medica l device types.
Class

II

devices ,

such as

cardiac monito rs,

anesth esia

machine s and defibr illator s, were subjec t to perform ance standar ds
in additio n to genera l contro ls. A perform ance standar d was a set
of specifi cations that the device must meet to be safe and
effecti ve.
The process of develop ing a perform ance standar d was long and
difficu lt; and no standar ds had been put in place by then.
Approx imately 1,100 types of device s, or 65 percen t of the total,
were include d in Class II (Drew, 1986).
Class III devices were those with the greates t risk of injury,
or that support ed or $Ustain ed life and had an unknown degree of
risk. They include d artific ial heart valves, heart-l ung machin es,
and lithotr iptor.
Class III devices were subjec t to general contro ls and premarket approv al. This meant r.hat firms must obtain FDA approv al
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before marke ting the device .

~~y

device s that w~re uot marke ted

before the Medic al Device Amendments were autom aticall y Class III
device s (unles s FDA found that they were substa ntiall y equiva lent
to a Class I or Class II device ). Appro ximate ly 140 device s were
Class III, or 8 percen t of the total (Drew, 1986).
Pre-m arket approv al depend ed on the firm showin g that the
device is safe and effect ive, usuall y based on clinic al studie s or
other clinic al experi ence with the device . In order to develo p
clinic al data for such approv al, an invest igatio nal device
exemp tion (IDE) had to be obtain ed from FDA. An IDE permi tted
limite d distri bution under specif ic condit ions for the purpos e of
studyi ng the device . The IDE provid ed for the clinic al use of
device s at a specif ic number of locati ons, based upon labora tory
and animal tests which predic ted that clinic al use in humans would
be poten tially helpfu l to patien ts.
A number of regula tory requir ement s applie d to medic al device
firms after marke ting begins . The genera l contro ls ( includ ing
regi~t ration , listin g, and good manuf acturin g practi ces) contin ued
to apply. The Food, Drug, and Cosme tics Act requir ed that FDA
inspec t all medic al device manuf acture rs that produc e Class II or
Class III device s at least once every two years. Compa nies who made
only Class I device s were inspec ted at least once every four years.
FDA could inspec t a firm more freque ntly if proble ms occurr ed with
its produ cts.
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Amore recen t additi on to the post-m arketin g requir ement s was
the medica l device report ing regula tion, which went into effect in
1984. Under this regula tion, medic al device firms were requir ed to
report to FDA any death or seriou s injury that may be relate d to
one of their produ cts, as well as any malfun ction that could have
caused death or se:iou s injury .
The Medic al Device Amendments protec ted consum ers in an area
where the compl exity of the techno logy prohib ited them from
person ally assess ing the safety and effica cy of the produ cts used
to preven t, diagno se or treat their illnes ses. Althou gh there was
basic agreem ent within the medic al device indust ry that FDA's
charge of imposi ng social regula tion was necess ary, many
manuf acture rs questi on the benef its versus the regula tory
expen diture s involv ed in compl iance.

Regula ted Indust ry Resear ch
In 1985, Ungson , J'ames

&

Spicer evalua ted the effect s of

regula tory agenci es on organ izatio ns in the wood produ cts and high
technc lcgwf/ electL onics indus tries. There were three distin ct but
relate d phases to their resear ch. First, they conduc ted prelim inary
interv iews with trade assoc iation s, regula tory agenc ies, and
select ed firms in the wood produ cts and high techno logy/e lectro nics
indus tries to improv e their unders tandin g of busine ss-gov ernme nt
relatio nship s. Second , they develo ped a survey questi onnai re, and
Page 30

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Time To Equiva lence
admini stered it to 80 firms in the two indust ries. They also
obtaine d regulat ory complia nce costs of some firms and used these
to corrobo rate questio nnaire respons es. Third, they conduc ted post
hoc intervi ews with manage rs of 14 firms to clarify questio nnaire
finding s and to elicit partici pants' reactio ns to the results .
Four specifi c hypothe ses were stated and tested. Hypoth esis
1 contend ed that sectors of the task environ ment varied in terms
of
importa nce,
predic tabilit y,
and
contro llabili ty
to
organiz ations. They found that governm ent regulat ory agencie s were
signifi cantly differe nt from all other sectors in terms of
predic tabilit y and contro llabili ty.
The

second

hypoth esis

contend ed

that

organiz ational

adjustm ents to differe nt sectors of the task environ ment varied.
They found, for the most, part that adjustm ents made in both
industr ies in respons e to regulat ory agencie s consist ed in hiring
and firing personn el and minor changes in work standar ds and
proced ures.
The

third h~,t:IOthesis

differe d in terms

contend ed that

regulat ory agencie s

of how their positio ns were perceiv ed by

organiz ations, and that these differe nces hold among industr ies.
They found the frequen cy of inspect ions and di£ f icul ty in obtaini ng
regulat ory inforlli ation had consequ ences upon m~~ale and were the
most severe adverse charac teristic s of regulat ory agencie s.
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The fourth hypothe sis contende d that assessme nts of agency
issues varied with the size and age of the £inn. They found that
larger, older f inns granted greater importan ce to regulato ry
agencies in their planning activiti es. Younger,
perceive d more hannful effects

smaller £inns

on morale arising from their

interact ions with regulato ry agencies than did older and larger
firms.
Within the medical device industry McKay (1986) attempte d to
in~estig ate the effects of the 1976 federal regulati on amendme nt
within the diagnos tic imaging industry . He question ed how the
medical device regulati on effected net entry (e.g., the differen ce
between the number of finns entering and exiting and industry ) and
concentr ation (e.g., the distribu tion of sales among finns in the
industry ).
Regressi ons coeffici ents were produced for both net entry and
concentr ation spanning years 1970 to 1980. He found that medical
device regulati on did not appear to signific antly effect net entry
or concentr ation in the diagnos tic imaging equipmen t industry .
Research Studies
Parket

Eilbirt (1975) attempte d to measure the absolute net
income, profit margin return on equity, and earnings per share.
&

Ninety-s ix firms responde d to a survey. The profitab ility of 80 of
these finns were compared to Fortune 500 firms. On all four
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measur es, the 80 firms proved to be more profita ble. Some of the
limitat ions of the study include d no adjustm ent for risk. There was
a questio nable sample; perform ance was measure d over a short period
of time ( 12 months) ; perform ance criteri a were inadequ ate; no tests
for signifi cance were perform ed.
Heinz (1976) stipula ted severa l measure s such as return on
assets, return on equity, and profit margin s. He correla ted
Corpor ate Social Respon sibility (CSR) ratings of 29 firms from a
Busines s and Society Review survey with ret·~rn on equity. A
signifi cantly

positiv e

correla tion

between

corpor ate

social

respon sibility and return on equity was found. Howeve r, the small
sample size and relianc e on a reputat ional rating system were
limitat ions.
Sturdiv ant

&

Ginter (1977) establi shed perform ance criteri a

of earning s per share over a ten year period. A popula tion of 67
high Corpor ate Social Respon sibility (CSR) firms as identif ied by
Moskow itz in the Busines s and Society Review were used in a survey.
Twenty -three

firms

returne d

130

questio nnaires .

The

67

firm

popula tion was also reduced to 28 firms and reclass ified into four
indust rial groupin gs. Their researc h implied that high CSR firms
{Best and Honora ble Mention ) outperf ormed low CSR firms. This study
did not provide an adjustm ent for risk. They employe d a t-test with
a

very

small

incons istent.

sample
They

also

and

the

failed

indust rial
to

identif y

catego ries
a

were

c11-."'"Vilinear
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relatio nship

reveale d

in

the

data

between

corpora te

respon sibility and earning s per share.
Alexand er and Buchho lz (1978) measure d stock price increas es
over two years and five years. They used reputat ion ratings derived
from Busines s and Society Review surveys . Corpor ate Social
Respon sibility (CSR)

ratings were correla ted with stock price

increas es over time and adjuste d for risk. They determi ned that CSR
had no effect on stock market perform ance. This study seemed to belimited by relianc e on a questic nable sample and the perform ance
measure s were inadequ ate.

Summary
The role of governm ent had been primar ily to suppor t busines s
systems in their role of econom ic leaders hip and to mediate between
busines s and society . Govern ment's role had changed from judging
how well busines s perform ed its social respon sibiliti es -co definin g
what these respon sibiliti es should be. The role of governm ent was
enlarge d to include a regulat ory functio n. A wave of legisla tive
regulat ion of busines s followe d. The rapid expansi on of governm ent
control s had been associa ted with a growing dissati sfactio n with
the effects of regulat ions.
widely accepte d divisio ns of governm ent regulat ion were
econom ic and social. The basic reform strateg y, accordi ng to
Two

Bardach and Kagan ( 1982), had animate d the growth of federal
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protect ive

regulat ory program s

and had created

a

series

of

regulat ory agencie s, all for the purpose of the betterm ent and
improve ment, both sociall y and econom ically, of the operati on of
busines s and industr y.
The medica l de7ice industr y had been subjec t to both social
and econom ic regulat ion. Food and Drug Admin istratio n (FDA) was the
designa ted regulat ing agency respon sible for creatin g and issuing
guideli nes for the medica l device industr y. Severa l regulat ory
develop ments in the medica l device industr y culmin ated in the
enactme nt of the Medica l Device .Amendmente of 1976. The econom ic
and social consequ ences of these amendm ents have beer- evaluat ed
since their enactm ent.
The researc h studies which had been reviewe d were related to
social regulat ion and profita bility in severa l regulat ed
industr ies. One study surveye d manage rs in the wood and high
techno logy/el ectroni cs industr y as to the social and econom ic
consequ ences of federal social regulat ion. A second study looked
at net entry and concen tration in the diagno stic imaging equipm ent
industr y.
Furthe r researc h studies were reviewe d that employe d survey
questio nnaires in evalua ting organiz ational perform ance with
respect to corpora te social respon sibility .
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CHAPTER III

METHODOLOGY

Introdu ction
The study examine d aspects of the impact of fedAr~,

Qnc;~1

regulat ion upon the time require d to get a medica l device through
the FDA review process and onto the market for small and large
firms

in

the

accomp lishmen t

orthopa edic
of

the

study

medica l

device

necess itated

quanti tative and opinion data from a

and differe nces

the

collect ion

The
of

geogra phicall y dispers ed

popula tion of regulat ory affairs manage rs.
relatio nships

industr y.

Data describ ed the

between elemen ts

of

indepen dent

variab les, company charac teristic s, manage rs' opinion s, and the
depend ent variab le, time to equival ence or FDA dispos ition.
The

method s

of

researc h

adopted

were

descrip tive

and

compar ative in nature. Accord ingly, the design involve d descrip tive
and compar ative quanti tative and qualita tive data collect ed via a
survey method.
The researc h questio ns were as follows :
1.

What

is

the

relatio nship

between

time

devoted

to

establi shing an FDA dispos ition of substa ntial eauival ence for an
orthopa edic medica l device and related costs and resourc e
consum ption?
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2.

Is there any differe nce between respond ents (compa nies)
who possess or do not possess certain identif ied charac teristic s
and time require d to establi sh equival ence?
3.

Is there a any differe nce between time to equival ence and
respon dent's (compa ny's) attitud es about selecte d charac teristic s
of

the

regulat ory

process

as

having

an

impact

on tir~e

to

equival ence?
4.
predic ts

What combin ation of indepen dent variabl e measure s best
time to equival ence? This researc h questio n takes

inform ation from all the questio ns on the questio nnaire.
5.

What variabl es appear to have an impact on time to
equival ence as perceiv ed by the company respond ent? This researc h
questio n relates to questio ns number 4 and 10 on the questic nnaire.

Choice of Method
In the classic al formula tions of how best to apply social
researc h to organiz ational behavi or, one of the recomm ended
earlies t steps was to develop intellig ence about the problem in
questio n. This process include d forming adequa te concep tual and
empiric al definit ions, and assemb ling or gatheri ng suffici ent
empiric al data to provide a descrip tion of the problem in terms of
its size, organiz ational locatio n, and spatial distrib ution of the
problem in questio n.
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The preces s descri bed above has been attemp ted, to varyin g
degree s of succes s, throug h the use of survey s invest igatin g
profit abilit y and organ izatio nal behav ior.

Parket and Eilbe rt

(1975) explor ed the profit abilit y of 80 firms compa red to Fortun e
500. Their perfor mance criter ia were absolu te net income and profit
margin ~ Heinz (1976} correl ated Corpo rate Social Respo nsibil ity
with severa l measu res such as return on equity and profit margin s.
He employ ed Busine ss and Societ y Review survey rating s to compar e
29 firms on profit abilit y.
Sturdi vant

and

Ginte r

(1977}

had

23

firms

return

130

questi onnair es queryi ng execu tives regard ing profit growth over 10
year period . In additi on, a classi ficati on proced ure was employ ed
to recate gorize 67 sample d firms into four indus trial groupi ngs.
Alexan der and Buchho lz (1978) used reputa tion rating s derive d from
Busine ss and Societ y Review survey s. Social respo nsibil ity rating s
were correl ated with stock price increa ses over time and adjust ed
for risk. Auppe rle, Carro ll,

&

Hatfie ld (1985) used a forced -

choice survey instru ment contai ning 20 items assess ing strate gic
manage ment and profit abilit y. Eight hundre d and eighte en chief
execut ives listed in Forbes 1981 Annual Direct ory were sample d.
Ginsb erg's disser tation work ( 1986) at the Unive rsity of
Pittsb urgh measu red enviro nment al attrib utes, organ izatio nal size,
and perform ance throug h the use of a questi onnair e. Questi ons were
design ed to invest igate the changi ng compe titive enviro nment of
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financi al

de:f>C ·dtory institu tions

since the enactm ent of the

Deposi tory Institu tions Deregu lation and Moneta ry Contro l Act in
1980.

Resnic k's dissert ation (1986) focused on the airline industr y
just after

governm ent deregu lation

in 1978.

He

attemp ted to

determi ne what corpora te policie s and practic es resulte d from
extern ally imposed events requiri ng critica l judgmen t and how those
policie s and practic es affecte d employ ee educati on and trainin g
program s as reporte d by corpora te trainin g directo rs. The study
selecte d the largest U.S. airline s, as identif ied by employ ee size
in 1984 and listed in the 1984 U.S. Airline Handboo k.
As

evidenc ed by the use of guesti,_,,., ..... .;.,.~d cited above, a

survey design which utilize s a questio nnaire comple ted by top level
executi ves is a viable and well recogn ized procedu re for obtaini ng
standar dized

inform ation

about

organi zationa l

behavio r

and

charac terist:i cs.
The

survey

design

that

was

implem ented

in

this

study

represe nted an attemp t to achieve a satisfa ctory tradeo ff between
the goals of genera lizabil ity, contex tual realism , and precisi on.
Survey designs have three basic charac teristic s: (1) system atic
measure ments were made over a series of cases yieldin g a rectang le
of data; (2) the variabl es in the matrix were analyze d to see if
they show any pattern s; and ( 3) the subjec t matter was social
(Marsh, 1982).
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Babbie (1973) identif ied three basic types of survey designs :
(1) cross-s ectiona l surveys ; (2) longitu dinal surveys ; and (3)
c~o~s- section al surveys that approxi mate longitu dinal ones.
In a cross-s ectiona l survey, data were collect ed at one point
in time from a sample selecte d to describ e some larger popula tion
at that time. In a longitu dinal survey, data were collect ed at
differe nt points in time and the researc h was able to report
changes in descrip tions and explan ations.
Major example s of longitu dinal designs were trend, cohort or
panel studies . Trend studies collect ed data from the same genera l
popula tion at differe nt times. Cohort studies collect ed data from
the same specifi c popula tion at di£ ferent times. Panel studies
collect ed data from the same specifi c sample at differe nt times.
In an "approx imately longitu dinal" survey, the data were
collect ed at one point in time. Questio ns were present ed which
involve d some notion of actual and perceiv ed changes at differe nt
points in time.

Exampl es of these questio ns were changes

in

employe e size at progre ssive one year interva ls from 1976 to
presen t and perceiv ed influen ce of regulat ory docume nts produce d
by the federal governm ent which stipula ted guideli nes at
progres sive one year interva ls.
Some schol;;. rs might argue that researc h on organiz ational
change can only be conside red genuin ely longitu dinal when data are
collect ed at differe nt periods of time. Miller

&

Friesen (1982)
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defined longitu dinal researc h as "those techniq ues, method ologies
and activit ies which permitt ed the observ ation, descrip tion, and/or
classif ication of organiz ational phenom ena in such a way that
process (i.e. , any sequenc e of changes in organiz ational variab les)
can be identif ied and empiri cally docume nted".
Given the difficu lties involve d with collect ing panel data
(e.g. expens ive, require a long time to collec t, and face problem
of

sample attriti on),

a

broade r definit ion of

"approx imately

longitu dinal" was employe d in order to suppor t the utiliza tion of
uapprox imately longitu dinal" designs that used retrosp ective data
collect ion in investi gating profita bility and regulat ions.
Gregson

(1975)

and

others

found

that

descri~ tions

of

histori cal events become increas ingly unrelia ble over time. This
was due to loss of memory and the recency effect (i.e., the
tendenc y to rationa lize and distort accoun ts of past behavio r in
terms of subsequ ent and more recent events and conditi ons).
Nevert heless, there were also studies which showed that there
was

no

signifi cant

differe nce

in

accurac y

between

recalli ng

behavio r which occurre d 10 or more years ago and behavio r which
occurre d two or three months ago (Gutek, 1978). It had also been
shown

that

retrosp ective

recall

of

past

earning s

was

not

substa ntially less accura ts t:han tha.t obtaine d for curren t salary
(Ferber & Birnbau m, 1979).
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Moreov er, Powers, Goudy,

&

Keith (1978) conduct ~d a study

which indicat ed that while recall techniq ues may have little
utility for descrip tive purpos es, they may be used cautiou sly in
correla tional studies . Finally , there was evidenc e which showed
that survey methods employ ing collect ion of retrosp ective or recall
data were reliabl e provide d certain precaut ions (such as not asking
respond ents to describ e events that have a strong emotio nal
compon ent regardi ng themse lves) were taken (Moss & Goldste in, 1979;
Power

&

Huber, 1982).

Researc h Popula tion
Althoug h medica l equipm ent compan ies in this country have had
a fairly stable and rapidly growing econom ic and techno logical
environ ment, orthopa ed.lc medica l device manufa cturers have been
directl y touched by regulat ory change due to the risk they pose.
Other

reasons

for

orthopa edic medica l
represe nt a

focusin g
devices

on

compan ies

include the

relativ ely homoge neous group;

that

followi ng:
{2)

manufa cture
(1)

they

they represe nt

approxi mately 10-15% of the 40,000 - 50,000 medica l devices that
cover the 1700 types sold in the U.S. and will be used at least
once by each man, woman and child in this country and many others;
(3) access ibi!.ity to regulat ory affairs manage rs is relativ ely
high.
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Data sourc es were small and large ortho paedi c medic al devic
e
manu factur ing firms throu ghout the Unite d State s. Selec tion
of
firms began with a review of The 510(k ) Regis ter in which
was
liste d all compa nies that have filed SlO(k ) prema rket notif icatio
ns
since the enactm ent of the 1976 medic al devic e amend ment.
The
SlO(k ) Regis ter provi ded a produ ct index which distin guish
ed 19
diffs rent medic al devic e class ifica tions of which ortho paedi
c was
one. Withi n each class ifica tion was a produ ct codin g system .
Firms

we~e chose n from produ ct codin g categ ories which had no less
than
ten firms repre sente ~. There were two reaso ns fox this selec
tion
proce ss: ( 1) these categ ories repre sente d compa nies that
were
diver se in terms of size and numbe r of produ cts manu factur ed,
and
(2) these compa nies funct ioned in the most comp etitiv
e marke ts.
Instru menta tion
resea rcher -desig ned surve y quest ionna ire was const ructe d to
enabl e speci fic categ oriza tion of data. The most appro
priate
A

techn ique of obser vatio n for colle ction of data from
firms '
manag ement was throu gh use of a quest ionna ire. But a review
of the
litera ture showe d no stand ardiz ed instru ment had been devel oped
to
measu re

the

resea rch

dimen sions

of

the

relati onshi ps

and

comp arison s among the parti cular varia bles of the prese nt resea
rch.
The final instru ment consi sted of a lette r of trans mitta
l
(Appe ndix B) and a quest ionna ire (Appe ndix C) with instru ction
s.
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The questi onnair e was design ed to captur e quant itative data
and to quant ify opinio n duta. =he questi onnair e consis ted of three
pages. The first two pages contai ned tables which provid ed the
subjec t with a quant itative framew ork throug h which relatio nship s
and compa risons could be made from 1977 throug h 1987. The third
page

contai ned

a

table

which

provid ed

the

subjec t

with

a

qualit ative framew ork throug h which compa risons among elemen ts of
variab les could be indica ted quant itative ly.
The design of the questi onnair e was guided by two primar y
object ives: 1) assure the captur e of compl ete data, and 2)
facili tate the ease and speed of compl etion. As a result , the first
two pages of the survey consis ted of binary respon ses or short,
numeri c fill-in s. This consti tuted a combin ed closed and open form
questi on design .
Since the princi pal object ive of this study was to evalua te
the influe nces on timely compli ance over time ( 1977 - 1987),
questi ons one throug h four were ordere d chron ologic ally. This
allowe d for histor ical compa risons and associ ations with events in
indust ry and govern ment. In additi on, initia l, pre-st udy interv iews
with regula tory affair s manag ers in which open-e nded questi ons were
asked indica ted that contin uity and clarit y would be preser ved if
the questi onnair e was design ed as presen ted in Appen dix C.
Questi ons five throug h ten were also design ed to evalua te the
influe nces on timely compl iance. Questi ons five throug h nine were
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constr ucted as Liker t attitu de scales . Favora ble or unfavo rable
attitu des on five Likert -type catego ries were reques ted. Althou gh
the respon dents were famili ar with the subjec t matter , a "no
opinio n" catego ry was suppli ed as one altern ative to assure that
each questi on was compl eted. Questi on ten was includ ed as an openended query design ed to yield inform ation which may not have been
addres sed on the questi onnai re. Althou gh the pilot study which was
incorp orated into this resear ch had as one object ive the
priori tizati on of questi ons, it was felt that the respon dents
needed one other vehic le to expres s their percei ved influe nces on
timely compl iance.
The letter of transm ittal was design ed as sugges ted by Borg
and Gall (1979) . Those intent ions which guided the design of the
transm ittal letter were as follow s: 1) give the respon dent a good
reason for compl eting the questi onnair e, 2) explai n the purpos e of
the study, 3) refere nce the respon dent's profes sional status , 4)
empha size the import ance and signif icance of the study, 5) assure
the respon dent's anonym ity, and 6) offer to send the respon dent a
copy of the result s.
In additi on, the transm ittal letter was refine d throug h the
pilot study. The partic ipants were asked to evalua te the
transm ittal letter with regard to compo sition, raalis m, accura cy,
and releva ncy. Appen dix A includ es the pilot study cover letter .
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Pilot Study

A pilot study was incorpor ated due to the lack of research
documen ted in the literatu re which provided informat ion relevant
to this research . Min~l informat ion was availabl e about the
medical device industry , regulato ry professi onals, the regulati on
of medical devices, and the interact ion of all three.
In an effort to standard ize and validate the content, format,
and delivery of the research question naire,

a

represen tative

were

medical

device

manufac turers

sample of
asked

14
to

particip ate in the pilot study. This selectio n process, although
not subjecte d to any form of randomi zation, was purposiv e, The
pilot study par~icip ants were chosen based upon their knowledg e of
the industry , their willingn ess to particip ate, and their interest
in the research project.
Six particip ants or question naire evaluato rs were queried via
the mail. A cover letter solicitin g their assistan ce in the pilot
study (Appendi x A), the transmi ttal letter (Appendi x B), and the
questio!U laire (Appendi x C) were forwarde d. Their comments were
requeste d regardin g both the transmi ttal letter and question naire.
Eight particip ants or reviewer s were interview ed by this
research er at the 1989 Annual Regulato ry Professi onal Society
meeting in Washingt on, D. C. Comments were sought regardin g the
content and validity of the question naire. Specific ally, these
reviewer s

were

asked

to

consider

each

question naire

item's
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relevan ce to the purpose of the study, that is, timely complia nce.
The logic and soundne ss of each item was assesse d. Then the
questio nnaire was reasses sed as a compos ite entity. This form of
evalua tion primar ily consist ed of face validit y compar isons rather
than conten t validit y. In additio n, since no criteri on measure s
were availab le with which to correla te the questio nnaire items,
predic tive and concur rent validit y checks were not possib le.
Do to the nature of the test or questio nnaire,

it was

difficu lt to calcula te a coeffic ient of interna l consist ency or
equival ence. As a result, the unavai lability of an alterna tive form
of the questio nnaire mandate d the calcula tion of a coeffic ient of
stabili ty only.
Further more,
this
test-re test reliab ility
measure ment

was

limited

to

four

respond ents.

The

delay

in

admiui stration was one day, approxi l4ately 24 hours. The reliab ility
coeffic ient was compute d to be 89%.
Howeve r,

this

meeting

in Washin gton permitt ed pre-stu dy

establis hment of baselin e variabl e values . All of these respond ents
were regulat ory affairs profess ionals activel y employe d within the
medica l device industr y.
All sugges tions and commen ts were collect ed. Sugges tions were
incorpo rated if consens us (more than one reviewe r had a similar
concern ) was reached regardi ng a variab le. One consequ ence of this
review process was the elimina tion of two questio ns which focused
on the direct impact of complia nce upon time to equival ence as it
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relates to increased or decreased production costs. Most reviewers
felt

unqualified

to

supply

specific

information

regarding

production costs since this was not their area of expertise.
Overall,

the

reviewers

found

the

transmittal

letter

and

questionnaire did address the research questions being evaluated
in this research endeavor.

Procedures
Questionnaire Mailing
The survey design for this study entailed a transmittal letter
and

cp.!estionnaire

mailed

to

orthopaedic

medical

device

manufactures. The Director of Regulatory Affairs or the person
responsible for filing section SlO(k)s for the company was asked
to complete the questionnair~ and return it in a self-addressed,
stamped envelope.
The sample consisting of 27 different orthopaedic device
categories was drawn from a population of over 245 orthopaedic
device categories. These 27 device categories represented 5 Class
I devices, 21 Class II devices and 1 Class III device. Figure 1
below details

the

orthopaedic

device

classification category

supplied in The 510lk) Register and the FDA device classification
provided in the Federal Register (1987).
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Figure 1
Orthop aedic Device Classi ficatio n Categor y
and
FDA Device Classi ficatio n

Dav!ca category
Operating

Roam

DBV'ica Classificat ion

Accaascriaa

II

Bena Fixation Plata

II

Arthrcaccpe

II

F~tibia l, Sami-ccnstr ained !:nae Prosthesis

II

Intramedul. lary Fixation Red

II

Ren-powered Fixation Apparatua

II

Famcrotibi al, ll0n-c011Btr ained Xn- Prosthesis

II

Pnelllllatic Pcwaxad Surgical I11Btrumant

II

Forceps

I

Smccth P:ixaticn Pill

II

Orthopaedic cutting I11Btrulllallt (Saw)

II

Bena Pixaticn Screw

II

AC Pawarad Meter Surgical Instrument

II

Limb Brace Orthcsis

I

Cast, Ba.ndage

I

Semi-ccnstr aillad Elbcw Prosthesis

II

Semi-const rained Bip MatallPcly Prosthaais

II

Semi-co11Bt railled Bip Matal/Acata bular Prosthesis
Invasive Traction Ccmpcrumt

II

Semi-const rained !:nae Patallc/fam crotibial Prosth-is

II

II

DC Pcwared Surgical IllBtrumellt
Combined llail/Blacla lPlata Fixation Appliance

II

Bemi-famcr al !lip Metal Prosthaaia

II

Interl.am:l.n ar Spinal Fixation Appliance
R011-c0nstr ained, C11111m1tad Shoulder Prosthesis
Bami-famcr al !lip MetallPclyu m: Prcsthaaia

II

Cast Ccmpcnant

I

III
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The listing above constit uted 553 devices manufa ctured by 148
differe nt compan ies from 1976 to 1987. This sample was drawn from
over 950 orthopa edic devices manufa ctured by over 670 orthopa edic
medica l device manufa cturers . The rationa le for this sample
selecti on was based on a

selecti on criteri a that the device

categor y have a minimum of ten compan ies manufa cturing devices
between 1976 and 1988. The Sl0(K) Registe r lists all submis sions
by device categor y since 1976. A curso~ review of this docume nt
would reprodu ce with minima l comput ation this same list of
evalua ted catego ries.
One hundred and six of the 148 device manufa cturers were sent
questio nnaires . Contac t with 42 manufa cturers was not establi shed
due to relocat ion, non-ex istence , or insuffi cient inform ation.
Comple ted questio nnaires were returne d to the Univer sity of San
Diego.

Data Collec tion and Follow- up
Within

approxi mately two months,

28

questio nnaires

were

returne d for a return rate of 26%. Useful inform ation was availab le
on 24 of those 28 returne d forms. Among those four returne d forms
with unusab le inform ation, the most common reason given for lack
of respons e was the respon dent's feeling that he or she could not
supply approp riate inform ation.

Since the return of 24 forms

represe nted only 128 device submiss ions between 1976 and 1987 for
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a follow -up rate of 23%, furthe r inform ation was sough t throug h
phone interv iews.
The phone interv iew proces s was struct ured so that only one
indepe ndent interv iewer was utiliz ed. A phone contac t scenar io was
constr ucted which facili tated the gather ing of inform ation simila r
to that obtain ed on the mailed questi onnair e. Phone interv iews took
4 - 5 minute s to compl ete. Appro ximate ly 8 - 10 hours were devote d
to the phone interv iew proces s. Less than 5% of those contac ted
refuse d to partic ipate in the study. Most partic ipants were on the
East Coast and unava ilable for interv iew becaus e of confli cting
time frames , other obliga tions, or vacati ons.
additio nal. 15 mcm.u facture i:s were contac ted via the phone.
This sample was drawn from the remain ing 78 manuf acture rs who did
An

not return the origin al mailin g. The remain ing 78 compa nies were
priora tized based upon the number of submi ssions they had made
betwee n 1976 and 1987. This proces s was random ized in that not all
subjec ts were contac ted direct ly upon the first phone call. If a
respon dent was not reache d upon the first call, he or she was not
called again until the last subjec t on the list had been called .
The list was then initia ted again from the beginn ing.
The questi onnair e mailin g and the phone interv iews combin ed
to produc e 39 comple ted questi onnair es with a return rate of 37%.
This also increa sed the device submi ssion number to 263 for a
return rate of 47.5%.
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The Rese arch App roac hes and Data Ana lysi s
App roac h I
The firs t leve l of anal ysis dea lt with Rese
arch Que stion
Number l. The rese arch appr oach was a desc
ript ive- corr elat iona l
surv ey" !'t= purp ose was to dete ?:mi ne the rela
tion ship betw een thre e
cha ract eris tics of the orth opae dic med ical
devi ce man ufac turin g
company and time to equ. ival ence . Fox (
1969 J stat ed that a
~or rela tion al aurv ey was ~a surv ey desi gned
to esti mat e the exte nt
to whic h diff eren t vari able s are rela ted
to each othe r in the
pop ulat ion of inte rest ".
Lea st squa re regr essi on coe ffic ient s were deve
lope d base d upon
the stra ight -lin e rela tion betw een two vari able
s sum mari zed in the
follo wing equ atio n:
y = B0 + B1:c + s

•

In an effo rt to bett er repr esen t how the depe
nden t vari able
rela ted to the inde pend ent vari able s, a curv
ilin ear mod el was also
deve lope d. Poly nom ial equa tion s and qua
drat ic mod els were
repr esen ted by:
y = b 0 + b 1z + b~

Thes e anal yses were stra tifi ed by year , if
data perm itted .
The App endi x o surnrnari.zes the hypo thes es rela
ted to Rese arch
Que stion Number 1.
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Approa ch II
The second phase of the analys is address ed Researc h Questio ns
2 and 3. This analys is compare d 2 to 5 levels of 10 indepen dent
variabl es with one indepen dent variab le, t;me to equiva lence. Since
all compar isons involve d two or more groups, one-way analys is of
varianc e (ANOVA) was utilize d to detect differe nces between groups
or indepen dent variab le levels.
ANOVA involve d decidin g if the variati on due to differe nces
between groups was larger than would be expecte d by chance. If the
error variati on represe nted the natural variati on that would be
expecte d with chance, and if the variati on between groups was large
relativ e to the error variati on, the group means were likely to be
differe nt.
Howeve r, the assump tions underly ing the F-distr ibution of the
ANOVA were not met in most compar isons. When the assiwp tions
underly ing

ANOVA

were

tested,

it

was

determi ned

that

imbalan ces and group varianc es existed for most groups.
result; the ANOVA analogu e,

data
As

a

the Kruska l-Walli s test was used.

Kruska l-Walli s chi-squ are approxi mations were

t.~a:ited

for

each

analys is of varianc e.
These analyse s were stratif ied by year! if data permit ted.
Append ix E summar izes the hr.;,ot,n eses related to Researc h
Questio ns 2 and 3.
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Approac h III
This applied to Researc h Questio n Numbers 4. This third level
of analys is was the statist ical task of calcula ting regress ion
coeffic ients and beta weight s. Since the regress ion coeffic ients
could not be compare d agains t one another in an attemp t to
determi ne which of the various predic tor variabl es was the best
predic tor variab le, conver ted beta weights were compute d. Beta
weights were determi ned for each predic tor vari~~ le. The predict or
variabl e that had the largest beta weight , disrega rding whethe r the
beta weight was positiv e or negativ e, was the best predic tor.
if

Signifi cance levels were establi shed at 0.05 when evalua ting
a particu lar beta weight wa.s differe nt from zero. If a

particu lar predict or variab le was not helping very much to decreas e
the differe nce between the predict ed and actual criteri on scores,
then the beta weight for this predic tor variabl e will be close to
zero.
This analys is was restric ted to inform ation represe nting the
most recent company status. Therefo re, compar isons were made for
1987 only.
Append ix F summar izes the hypothe ses related to Researc h
Questio ns 4.
Approac h IV
This fourth level of analysi s was primar ily descrip tive. It
address ed inform ation supplie d through questio ns 4 and 10 on the
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questi onnair e. These questi ons reques ted the respon dent supply
opinio n inform ation. This yielde d data which was qualit ative in
nature and nomin al on type.
Freque ncy tables were genera ted. Tende ncies were evalua ted
throug h impose d strati ficati ons relati ng to the follow ing
condit ions: numbe r of years manuf acturin g medic al device s, number
of employ ees in the organ izatio n, number of device s manuf acture d,
presen ce of an in-hou se regula tory depart ment, use of outsid e
regula tory consu l~ants , and regula tory traini ng experi ences.
All statis tical analy sis, runs, tables and graphs are produc ed
throug h PC based SAS statis tical packag e. The SAS proced ures which
wex-e employ ed were FREQ, REG, ANOVA, and NPARlWAY.
Criter ia for Data Source s
Severa l criter ia were used to select data source s and includ e
the follow ing:
Criter ia 1. Docum ents have to be relate d to orthop aedic medic al
device firms in the United States .
Criter ia 2. Select ed device catego ries have no less than ten
device s manuf acture d betwee n 1976 and 1988.
Criter ia 3. Select ed firms have a regula tory affair s depart ment and
manag er or some person respon sible for regula tory affair s.
Criter ia 4. The person within each firm to whom the reque st for
data was addres sed was the regula tory affair s manag er or person
respon sible for filing Sl0(k) s.
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Surnrnary
The chapte r present ed the method o!ogy by which the researc h
design was produce d. The study examine d the relatio nship among
three indepen dent variabl es and one depend ent variabl e~ time to
equival ence. The study further compare d differe nces between twelve
indepen dent

variabl es

and

one

depenc!E:;r.t

variab le,

time

to

equival ence. Data were collect ed from a popula tion of small and
large orthopa edic medica l dev·ice manufa cturing compan ies dispers ed
through out the United States.
To

accomp lish

the

study,

a

mailed ,

researc her-des igned

questio nnaire was used. Phone intervi ews were also employe d to
facilit ate follow- up and clarify subjec t respons es. Validi ty and
reliab ility of the instrum ent were discuss ed based upon a pilot
study conduc ted to determi ne necessa ry changes in the instrum ent.
The procedu re of the experim ent was specifi ed in this chapte r
and the steps which achieve d selecti on of firms for the study were
outline d. Deline ation of the data collect ion process and follo,;1up rates was provide d.
This chapte r conclud ed witn design ation of the four researc h
approac hes and data criteri a which guided the statist ical analyse s
in this study.
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CHAPTER IV

DATA ANALYSIS

The chapte r present ed an analys is of data relativ e to the
relatio nship of three elemen ts of the indepen dent variab les,
organiz ational costs and resourc e consum ptions, and one depend ent
variab le, time to equival ence (days). These relatio nships were
evaluat ed over time. Furthe r analys is include d the measure ment of
mean differe nces in time to equival ence for five elemen ts of the
indepen dent variab le, organiz ational charac teristic s. Additio nal
analysi s was perform ed relativ e to the mean scores of the depend ent
variabl e, time to equival ence, and the five indepen dent variab les,
five classes of attitud es toward perceiv ed influen ces on time to
equival ence. The relatio nship relativ e to all twelve elemen ts of
the indepen dent variab le, organiz ational charac teristic s, and the
depende nt variab le, time to equival ence, were also analyze d. The
last analys is with regard to the respon dent's perceiv ed influen ces
on timely complia nce was descrip tive in nature.
the

These analyse s were made for the five researc h questio ns. For
first questio n regardi ng the relatio nship of time to

equival ence and organi zationa l costs and consum ptions a regress ion
line was fit to describ e the relatio nship. For the second questio n
regardi ng differe nces in time to equival ence relativ e to specifi ed
company charac teristic s, compar ative analys is was perform ed over
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time. The third quest ion germa ne to time to equiv alenc e and
five
class es of attitu des also invol ved comp arativ e analy sis. The
fourt h
quest ion requi red regre ssion coeff icien ts be conve rted into
beta
weigh ts to best predi ct time to equiv alenc e. The five quest
ion
entai led frequ ency distri butio ns of perce ived influe nces on
time
to equiv alenc e.
Unit of Analy sis
Altho ugh s~rve y resea rch provi ded techn iques for exami ning
pract ically any unit of analy sis, typic ally such units
were
perso ns • Neve rthele ss, numer ous surve ys ~ave been condu cted
in
order to gathe r inform ation from iI&div iduals or "infor mants "
about
organ izatio n-lev el varia bles such as strate gy or prof it influe
nces.
Venka trama n and Grant (1986 ) have ident ified two appro aches
that have been commonly adopt ed for opera tiona lizing organ izatio
nlevel const ructs . One appro ach was the colle ction of data
f~om a
desig nated execu tive with an impli cit assum ption that the respo
nses
refle ct organ izatio nal chara cteri stics of inter est. The
secon d
appro ach sugge sted the colle ction of data from multi ple respo
ndent s
from which the mean was calcu lated to repre sent an organ izatio
nal
score .
This study utiliz ed the first appro ach sugge sted above . The
Direc tor of Regul atory Affai rs or the execu tive respo nsibl
e for
filing secti on Sl0(k )s was the desig nated subje ct who suppl
ied
respo nses.
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Medical Device Categories

The questionnaire and phone interview processes resulted in
the return distribution illustrated in Figure 2 below. The device
categories were listed in the sequence provided through the 510(kl
Register. The second column in Figure 2 headed by Comp. represented
the number of companies with device submissions to FDA in each
device category. The third column headed Sub.listed the number of
device submissions among the indicated companies and within a
specified device category.
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Figure 2
Orthopae dic Medical Device Categori es,
Number of Compani es, and
Number of Device Submissi ons per Category
Da,rice category

Comp.

Sul>.

l

Operating Jlocm Accaaaoriaa

l

l

2

Bona Fi=tion Plata

4

6

3

Arthroscope

13

26

4

F-,rotibial, Semi-con. Enaa Proathaais

7

22

5

Intramadallu y Fixat1011 Rod

5

8

6

•on-powered Fixation Apparatus

6

11

7

F~tibiaJ., lion-con. Enaa Prostheaia

8

lO

8

Pna11111atic Powarad Surgical Inatrm.nt

4

4

9

Forceps

2

2

l!l

s.xith Fixation Pin

2

2

11

Orthopaedic cutting Inatrument (Saw)

2

2

12

Bone Fixation Screw

6

7

3

3

13

AC Powarad Mater Surgical Inatrm.nt

14

LilDb Brace Orthosis

l

l

15

cast, Bandage

2

2

16

Sami-conatrai nad Elbow Prosthesis

2

4

17

Bemi-con. Hip MatallPoly Proatheaia

19

58

18

e-1-con. Hip Matal/Acetabu lar Proa.

8

11

19

Invasive Tracti011 C0111p0nm1t

20

Sami-cona. ltnaa Patallo/Famor ot.ibial

Pro■•

4

8

11

27
2

21

DC Powered Surgical Inatrwaant

2

22

ec.l)ined !lllil/BladelP lata Pixat1011 Appl.

4

9

23

Bemi-!emoral Hip Metal Prosthesis

9

15
4

24

Iuterlaminar Sp1.nal. Fixation Appliance

3

25

5011-conatrain ad, Cemented Sllonlder

5

9

26

llaai-!amoral Hip MatallPol:ymer Proa.

7

8

27

Cut Cclaponant

1

l

Pro■•

Total

263
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The above listing supplied informatio n about the sample of
companies in this study who made submission s from 1977 through
1987. This represente d a homogeneou s sample of orthopaedi c medical
device categories . The purposive selection process provided for a
fairly homogeneous sampling. In addition, selection bias did not
seem tc influence the device distributi on.
The

following

section

described

the

results

of

this

investigat ion. All hypotheses were stated in the null,

Results of Analysis
Research Questions
Research Question Number l
What is the relationsh ip between time devoted to establishi ng
an FDA dispositio n of substantia l equivalenc e for an orthopaedi c
medical device and related costs and resource consumptio n?

Hypothesis 1.1. There is no relationsh ip between time (days)
needed to establish equivalenc e and the number of years a
company has been manufactu ring medical devices.
The equation for the fitted straight line was:
DAYS = b 0

+ b 1 YEARS
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Table 1 represe ntd the results of the least square regress ion
relatin g days tc the number of years manufa cturing medica l devices .
The princip le of least squares involve d fitting a line through the
points (i.e., days to equival ence) so that the vertica l differe nces
between all the points and the line were minimiz ed. The "best" line
was the line that minimiz ed the sum of squared differe nces, hence
the name least squares .

Table 1
Model Relatin g Variab le DAYS TO EQUIVALENCE to
Variab le YEARS MA?Wf';..CTURING

df

262

Intercept

73.067

Slope S.E.

-0.345 0.108

a-square

t-value

P-value

0.038

-3.203

0.001•

" - Signific11n t at 0.05 level

The equatio n for the fitted straigh t line with the values from
Table 1 inserte d was now:

Ti- to Equivalenc e(Days) - 73.067 + (-0.345)Ye ars Manufactu ring

By comple ting this equatio n, it was apparen t that 73.067 days

was the predict ed mean time to equival ence if zero was s..ibstit uted
for the number of yearia: manufa cturing medica l devices . This was the
value of time to equival ence (days) at the point where the fitted
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line interc epted the vertic al axis. Under these circum stance s, the
interc ept gave an estima te of the averag e numbe r of days requir ed
to establ it;h equiva lence when a compan y had no manuf acturin g
experi ence. The slope of the line was the amoun t of decrea se in
predic ted days to equiva lence that would result from an increa se
in one year of manuf acturin g experi ence.
As a result , the predic ted mean numbe r of days to equiva lence

for a compan y manuf acturin g medica l device s one year would be
72.722 days. The predic ted value for a compan y with five years of
manuf acturin g experi ence would be 71.338 days. The predic ted value
for ten years experi ence would be 69.608 days. The predic ted value
of 42.277 days result ed when consid ering the oldest compan y in this
study with 89 years manuf acturin g experi ence.
The R-squa re value of 0.0378 indica ted that little , if any,
of the variat ion in the data was accoun ted for in the propos ed
model. This value also reflec ted a low level magnit ude with regard
to the relatio nship of d.ays to equiva lence and ntilllber of years
manuf acturin g. The low level R-squa re value indica ted that other
variab les may have been needed in the equati on to accoun t for
variat ion in the data. Howev er, this findin g does not contra dict
the signif icance of the relatio nship which was found to exist
betwee n the number of years manuf acturin g and days to equiva lence.
The analys is relate d to Resear ch Questi on Number 4 below furthe r
illust rated the impac t of other variab les in the regres sion
equati on.
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However, upper and lower 95% predicti on limits were calculat ed
to further elaborat e on the magnitud e of this relation ship. These
calculat ions allowed for bounds to be put around a single predicte d
value. These bounds gave a probable range for the number of days
to equivale nce that were required given the number of years
manufac turing.

The magnitud e of the relation ship was

further

enhanced through thess computa tions since the predicti on limits
took into account the variatio n in the dependen t variable for
observat ions with the same value of the independ ent variable . These
limits also took into account any error in the fitted regressi on
line.
For

example,

a

company with

four

years

experien ce

in

manufac turing devices had an average predicte d time to equivale nce
equal to 71.68 days. The 95% limits were -27.88 and 171.2 days.
This meant that there was a 95% confiden ce level that the number
of days to equivale nce for a company with four years manufac turing
experien ce was somewher e between -27.88 and 171.2 days. This wide
of a range was a result of variatio n in days to equivale nce values
caused by factors othsr than the number of years manufac turing.
Realizin g the possible need for another term or factor in the
regressi on model which would better represen t the relation ship
between days to equivale nce and number of years manufac turing, a
quadrati c regressi on equation was introduc ed to fit the curve.
Table 2 below supplies the results of those computa tions.
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Table 2
Quadr atic Model Relati ng Variab le
to Variab le

YEARS

DAYS TO

EQUIVALENCE

MANUFACTURING

df

Intercep t

Slope

S.B.

R-aquare

t-value

P-value

262

83.026

o.ooe

o.oos

0.0473

1.609

0.109

The quadr atic model produc ed at-va lue for years (squar ed)
equal to 1.609 and statis ticall y signif icant at the 0.1088 level.
This indica ted that there was 1 chance in 10 of gettin g a tstatis tic as large as the one for years square d. This seemed to
sugge st there was no need for imposi ng the quudr atic model to
better repres ent the relatio nship betwee n days to equiva lence and
number of years manuf acturin g.
Althou gh a low-le vel correl ation seemed to exist betwee n days
to equiva lence and numbe r of years manuf acturin g, Table 1 did
provid e other =eleva nt inform ation. The t-valu e of -3.203 with the
proba bility of 0.0015 reject ed the null hypoth esis that the slope
equale d zero. The p-valu e for the t-valu e of 0.0015 suppli ed
eviden ce that tn~ slope was not zero. In other words , increa sing
the number of years manuf acturin g medic al device s did produc e a
statis ticall y signif icant decrea se in the number of days requir ed
to reach equiva lence.
In conclu sion, the null hypoth esis was reject ed in favor of
the altern ative that a relatio nship did exist betwee n the number
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of years manufac turing orthopae dic medical devices and the number
of days required to establis h equivale nce. Albeit the correlat ion
between number of years and days was equal to 0.194 and only 4% of
the differen ces among the companie s who manufa~ tured medical
devices

in terms

of

years was

predicta ble on the basis

of

differen ces in the days to equivale nce, increasi ng the number of
years a company manufac tures medical devices did produce a
statistic ally measurab le decrease in the number of days required
to establis h that a medical device was equivale nt to another device
manufact ured prior to 1976.

Hypothe sis 1.2. There is no relation ship between time (days)
needed to establis h equivale nce and tte number of employee s
in an organiza tion.

Table 3 represen ts the results of the least square regressi on
relating days to the number of employee s in the organiza tion. This
analysis was applied to the years 1977 through 1987.
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Table 3
Model Relat ing Varia ble DAYS TO EQUIVALENCE to
Varia ble NUMBER OF EMPLOYEES IN ORGANIZATION
rear

df

Interce pt

1977

137

58.697

-0.003 0.010

1978

194

53.713

0.015

0.001

2.295

0.0228•

1979

194

54.083

0.015

0.001

2.330

0.0209•

1980

217

58.026

0.014

0.001

2.183

0.0301*

1981

217

58.997

0.014

0.006

2.100

0.0369*

1982

220

60.653

0.015

0.006

2.211

0.0241"'

1983

220

56.843

0.011

0.006

1.709

0.0888

1984

227

60.652

0.010

0.007

1.332

0.1843

1985

234

65.463

0.007

0.001

o.935

0.3509

1986

240

63.196

0.006

0.007

0.856

0.3928

1987

243

64.709

0.005

0.001

0.713

0.4763

••Sign ificant at

Sl~

o.os

S.E.

t-value

P-value

-0.256

0.7981

level.

The data liste d in Table 3 seeme d to indic ate that there
exist ed a posit ive relati onsh ip betwe en the numbe r of emplo
yees in
an organ izatio n and the numbe r of days neede d to estab lish
~-quivalen ce. 'l'he only excep tion to this premi se was in 1977 where
there seeme d to be a negat ive relati onsh ip.
One

possi ble

relati onshi p

in

reaso n

for

the

was

the

fact

1977

existe nce
that

the

of

a

1976

negat ive
amend ment

posit ioned both FDA and indus try in an arena that was new for
both.
FDA was unedu cated and did not requi re all regula tior_.3 be
met;
thus, estab lishin g equiv alenc e in a short er perio d of
time.
Indus try, realiz ing a «ood to satis fy new feder al regul
ation s,

Page 67

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Time to Equival ence
employe d more personn el to meet these new regulat ory demand s.
Conseq uently, as the number of °"'Ploye es rose, time to equival ence
decline d.
Albeit , the years from 1978 to 1982 seemed to provide evidenc e
at the 0.05 signifi cance level that the pattern observe d in 1977
was being reverse d:
increas ed

so

did

as the number of employ ees in a company
the

number

of

days

needed

to

establi sh

equival ence. Clarity regardi ng this trend was furnish ed again by
the status of the agency and industr y in unison. As the agency
matured in its regulat ory respon sibiliti es, so did the require ments
for complia nce. This natura lly increas ed the days to equival ence.
The medica l device industr y, as mention ed above, continu ed to bring
in more

employe es

to meet the

regulat ory require ments.

This

increas e in employe es was seen in many departm ents other than the
regulat ory departm ent. Those departm ents with new demands as a
result

of

assuran ce,

the

1976

Researc h

amendment

were:

and Develop ment,

manufa cturing ,
adverti zing,

quality

sales,

and

market ing.
Statist ically signifi cant relatio nships decline d or were nonexisten t from 1982 t~ 1987. In fact, the relatio nship seemed to
progre ssively decline as each year passed. The rationa le for this
I6v~la tica rested primar ily with industr y at this junctur e. FDA
continu ed to make regulat ory reques ts for complia nce and, as a
result~ time to equival ence increas ed. Howeve r, industr y
departm ents became saturat ed and discove red that continu ed employe e
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recruit ment was not reducin g time to equival ence.
Conseq uently, the null hypoth esis was rejecte d from 1978
through 1982. A positiv e relatio nship existed between time to
equival ence and the number of employe es in an organi zation. From
19i8 to 1982, organi zationa l employe e size increas ed as did time
to equival ence. The null hypoth esis was retaine d from 1982 to 1987.
The number of employ ees in the organiz ation did not have a
statist ically signifi cant impact time to equiva lence.
Hypoth esis 1.3. There is no relatio nship between time (days)
needed to establi sh equival ence and the number of employ ees
in the regulat ory departm ent.

Table 4 represe nts the results of the least square regress ion
relatin g days to the number of employe es in the regulat ory
departm ent. This analys is was applied to the years 1977 through
1987.
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Table 4
Model Relati ng Variab le DAYS TO EQUIVALENCE to
Variab le NUMBER OF EMPLOYEES IN THE REGULATORY DEPARTMENT
Year

df

Intercep t

Slope

1977

137

58.446

-0.451 1.042

-0.433

0.6658

1978

194

56.471

-0.245 1.088

-0.225

0.8223

1979

194

56.888

-0.423 1.145

-0.369

0.7124

1980

217

60.218

-0.926 1.035

-0.894

0.3721

1981

217

61.092

-1.092 1.049

-1.041

0,2991

1982

220

62.277

-1.275 0.977

-1.305

0.1933

S.B.

t-value

P-value

1983

220

59.974

-0.885 0.982

-0.901

0.3685

1984

227

63.794

-1.305 1.020

-1.279

0.2021

1985

234

67.870

-1.813 1.014

-1.789

G,0749

1986

240

65.444

-1.495 0.986

-1.515

0.1310

1987

243

66.804

-1.576 0.938

-1.680

0,0942

Review of Table 4 indica ted that the numbe r of days requir ed
to reach equiva lence seemed to increa se with time. There was no
consis tent eviden ce that there existe d a relatio nship betwee n the
numbe r of employ ees in a regula tory depart ment and the numbe r of
days necess ary to get a medic al device throug h the regula tory
review preces s.
Years 1985 and 1987 were the only years in which increa sing
the numbe r of employ ees in a regula tory depart ment seemed to
signif icantl y, althou gh not statis ticall y signif icant, decrea se at
the .10 level the number of days to equiva lence. Althou gh not
statis ticall y signif icant, the number of employ ees in a regula tory
depart ment did seem to negati vely impact the numbe r of days to
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equiva lence at every time interv al. In other words, it seemed
appare nt that an increa se in the number of employ ees in the
regula tory dep~ ent result ed in fewer days requir ed to establ ish
equiva lence. As time went on, regula tory employ ees increa sed and
time to equiva lence (days) decrea sed. This would seem to sugge st
that the time requir ed to get a device throug h the FDA review
proces s may be decrea sed by increa sing the number of employ ees in
the regula tory depart ment.

Resear ch Questi on Number 2
Is there any differ ence betwee n respon dents (comp anies) who
posses s or do not posses s certai n identi fied chara cteris tics and
time requir ed to establ ish equiva lence?
Hypot hesis 2.1. There is no differ ence betwee n the type of
medic al device manuf acture d and time to equiva lence.
Since the assum ptions of norma lity and homog eneity of the
param etric F-test were not met for this hypoth esis, the Krusk alWallis test was utiliz ed in an effort to make the study findin gs
more gener alizab le. The Krusk al-Wa llis test assume s that the
variab les under study have an underl ying contin uous distri butio n
and are measu red on at least an ordina l level. The result s of that
analys is is provid ed in Table 5.
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Table 5
Wilcox on Scoras (Rank Sums) for Variab le DAYS
TO EQUIVALENCE Class ified by Variab le TYPE OF DEVICE

Class

N

Expec ted

Std Dev

Mean Score

Class I

245

32340. 0

265.12

131.38

Class II

15

1980.0

243.50

151.43

Class III

3

396.0

111.50

85.00

Krusk al-Wa llis Test (Chi-S quare Appro ximati on)
CHISQ

= 2.9543

df

=2

Prob> CHISQ

= 0.228

The null hypoth esis was retain ed. The calcul ated chi-sq uare
value did not exceed the critic al value at the predet ermine d level
of signif icance (0.05) . There did not appear to be a differ ence
betwee n the type of medic al device s manuf acture d and the number of
days needed to estab lish equiva lence.
Inspec tion of the data seemed to indica te that Class I device s
had a lower mean days to equiva lence than Class II device s;
howev er, not statis ticall y signif icant. Since there were only three
Class

submi ssions within our sample ,

III

suspec t.

Howev er,

propo rtion

of

this

patter n

submi ssions

was

within

not

the

the mean value was
aberra nt

total

since

the

popula tion

was

approx imatel y distri buted as repres ented in Table 5.
The chi-sq uare value of 2.95 with prob> 0.228 was less than
the refere nce proba bility value of 0.25. There fore, there was a 25%
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chance that whatev er differ ence that existe d betwee n the types of
medic al device s as they relate d to days to equiva lence was not due
to random error. Thus, whate ver differ ences that seemed appare nt
did not signif y genuin e popul ation differ ences .
The

nonpa rametr ic

analog ue,

Krusk al-Wa llis

tests

were

perfor med for the follow ing hypoth eses relate d to Resear ch Questi on
Number 2. Tables 6 throug h 9 detai l the result s of that analys es.
All compa risons were strati fied by years 1977 throug h 1987.
Hypot hesis 2 • 2 • There is no differ ence betwee n compa nies
having in-hou ae _regul atory depart ments and compa nies that
don't

have

in-hou se

regula tory

depart ments

on

time

to

equiva lence.
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Table 6
Wilco xon Score s (Rank Sums) for Varia ble DAYS
TO EQUIVALENCE Class ified by Varia ble REGULATORY DEPARTMENT
Yellr

Clua

1977

Yea

203

127.49

Bo

60

147.25

Yes

203

127.49

Bo

60

147.25

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

B

Mean

Yes

~04

126.88

Bo

59

149.67

Yes

225

130.11

Bo

38

143.16

Yes

225

130.11

Ro

38

143.16

Yes

228

o.•29.96

Bo

35

145.36

Yes

228

129.96

Bo

35

145.36

Yes

235

130.51

Bo

28

144.50

~es

241

131.21

Bo

22

140.64

Yes

247

129.87

Bo

16

164.91

Yes

251

13C.51

Bo

12

163.17

df

CBISQ

Prob>CH ISQ

1

3.12

0.077

1

3.12

0.011

1

4.11

0.043*

1

0.96

o.328

l

0.96

0.328

l

1.23

0.268

l

1.23

0.268

1

o.85

0.358

1

0.31

c.s1e

!

3.19

0.074

1

2.11

0.146

••Sign ificant at 0.05 level.

The years 1977 and 1978 had signi fican t diffe rence s, althou gh
not stati stica lly signi fican t, betwe en group s at the .10 level
.
Furth ermor e,

the diffe rence in mean days

to equiv alenc e was

stati stica lly signi fican t at the .OS level in 1979.
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There appea red to be one prima ry reaso n for this findin g. In
an effor t to meet the new regul atory requi remen ts and
stay
comp etitiv e durin g the

initi al

years

of

the

1976

amendment

enactm ent, the medic al devic e indus try heavi ly recru ited regul
atory
profe ssion als from withi n the pharm aceut ical indus try.
These
indiv idual s had exper ience and had an imme diate impac t on time
to
equiv alenc e. In addit ion, the large r compa nies were more succe
ssful
in their recru iting endea vors since they could affor d the
more
talen ted regul atory profe ssion al. The exper ience which trans ferre
d
from the drug enviro nmen t culmi nated after appro ximat ely
three
years which resul ted in a stati stica lly signi fican t diffe rence
in
1979.

This level of signi fican ce did not emerg e again until 1986
when the numbe r of compa nies that did not have a regul
atory
depar tment declin ed to 16 from 60 in 1977. In addit ion, the
mean
days to equiv alenc e from 1977 to 1985 range d betwe en 140 and
150
days for compa nies that did not have a regul atory depar tment
.
Howev er, in 1986, the mean days rose to nearl y 165 days. This
would
seem to accou nt for the signi fican ce level of .07 being detec
ted.
No indus try or FDA circum stanc e was readi ly appar ent durin g
this
time frame .
The null hypot hesis was retain ed at the • 05 signi fican ce level
for all comp arison s, excep t 1979. The numbe r of days to equiv alenc
e
appea red to be indep enden t of the prese nce or absen ce of an
inhouse regul atory depar tment for all years aside from 1979.
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Thus, compan ies with regulat ory departm ents in-hous e produce d
statist ically signifi cant reducti ons in the time require d to
establi sh equival ence in 1979 only.

Hypoth esis 2.3. There is no differe nce between compan ies who
receive d regulat ory complia nce trainin g and compan ies who
didn't receive regulat ory complia nce trainin g on time to
equival ence.

Table 7 below reflect s the results of testing hypoth esis 2.3
by years 1977 through 1987.
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Table 7
Wilco xon Score s (Rank Sums) for Varia ble DAYS
TO EQUIVALENCE Class ified by Varia ble REGULATORY TRAINING
Year

Class

R

Mean

1977

Yea

153

126.75

Ro

7,;;o

139.40

Yea

,.,
1"'

126.75

Ro

1.10

139.40

Yes

189

124.21

Ro

74

151.88

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

Yea

189

124.21

Ro

74

151.88

Yea

210

128.43

Ro

53

146.16

Yea

213

128.29

Ro

so

147.81

Yes

214

128.35

Ro

49

147.92

Yes

221

130.59

Ro

42

139.43

Yes

226

131.41

Ro

37

135.62

Yea

226

131.41

Ro

37

135.62

Yes

226

131.41

Ro

37

135.62

••Sign ificant at

o.os

CBISQ

Prob>CBISO

1

1.74

0.187

1

1.74

0.187

1

7.04

0.008*

l

7.04

0.008*

l

2.30

0.129

1

2.67

0.102

1

2,64

0.104

1

0.48

0.490

1

0.10

0.755

1

0.10

0,755

1

0.010

0.755

df

level.

Upon review of the data regar ding hypot hesis 2.3, there did
not appea r to be a diffe rence in group means regar ding the numbe
r
of days to equiv alenc e. It appea red that regul atory train ing
did
not have a stati stica lly signi fican t impac t on time to equiv alenc
e.
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The only years that did not adhere to this finding were 1979 and
1980.

Compar ing groups did yield a .008 lsvel of signifi cance for
1979 and 1980. It was eviden t that there had been a 33% decreas e
from 1978 to 1979 in compan ies who had not receiv~ d regulat ory
trainin g. In additio n, the mean days to equival ence had increas ed
by 8% from 1978 to 1979 for those compan ies with regulat ory
trainin g. This pattern remaine d constan t through 1980. From 1981
through 1987 the differe nce between means remaine d neglig ible.
Once again, some reasons for this occurre nce resided in the
industr y and the agency. For the industr y, the years 1S77 and 1978
amounte d to lead years where regulat ory knowled ge was being accrued
at a fast rate, but with little consequ ence. Also, during these
years, the agency was in a develop mental stage with regard to
whatev er regulat ory trainin g that was being provide d. The agency
was just beginni ng to orient the Off ice of Small Manufa cturers
Assista nce (OSMA) to the needs of the medica l device manufa cturer.
In fact, the first article highlig hting the service s provide d by
DSMA was publish ed in 1979. This event may partia lly explain the
signifi cance achieve d in 1979 and 1980.
The reduced differe nce from 1981 through 1987 reflect ed the
diffusi on of the body of experie nce that was attaine d during 1979
and 1980. The level of skill across the industr y became diluted and
a fairly homoge neous group emerged with regard to regulat ory
knowled ge.

The arrival or departu re of

a

trained regulat ory
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professi onal did not have a statisti cally signific ant impact on
time to equivale nce from 1981 through 1987.
Therefor e,

days

to

equivale nce

seemed

independ ent

of

regulato ry training experien ce except in 1979 and 1980. The null
hypothes is was rejected for these years only. During 1979 and 1980,
regulato ry training did have a statisti cally signific ant influenc e
on time to equivale nce.

Hypothe sis 2.4. There is no differen ce between companie s who
manufac ture one medical device and companie s that manufac ture
more than one device on time to equivale nce.
Table 8 below reflects the results of testing hypothes is 2.4
by years 1977 through 1987.
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Table 8
Wilco xon Score s (Rank Sums) for Vari able DAYS
TO EQUIVALENCE Clas sifie d by Varia ble MORE THAN ONE DEVICE
Year

Claaa

B

Nean

1977

Yea

216

124.55

Bo

47

166.24

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

Yes

216

125.55

Bo

47

166.24

Yes

216

124.55

Bo

47

166.24

Yes

237

127.75

Bo

26

170.75

Yes

24"j

129.25

Bo

17

171.82
129.12

Yes

249

Bo

14

183.21

Yea

250

129.58

Bo

13

178.54
130.59

Yea

254

Bo

9

171.89

Yes

255

130.35

Bo

8

:i.84.56
130.97

Yes

259

Bo

4

198.62

Yes

260

130.91

Bo

3

226.83

DP

CHISQ

Prob>CB J:SQ

1

11.61

0.0007•

1

11.61

0.0007•

1

11.61

0.0007•

1

7.49

0.006•

1

4.98

0.026•

1

6.70

0.010•

1

5.12

0.024•

1

2.56

0.109

1

3.94

0.047•

1

s.12

0.077

1

4.72

0.030•

••Sign ifican t at 0.05 level

Table 8 indic ates that there was a diffe renc e at the .10
level
betwe en group s for all years inve stiga ted. In fact, that
diffe renc e
was very appa rent from 1977 throu gh 1983 wher e the
signi fican ce
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level was

• 05 or better.

Years 1984 and 1986 were the only

excepti ons to that finding .
The differe nce between means and the decline in the number of
compan ies manufa cturing only one device was notewo rthy. From 1977
through 1979 the average differe nce in means was 42 days while the
number of compan ies manufa cturing only one device remaine d constan t
at 47. In 1980, the number of compan ies who reporte d manufa cturing
only one device decline d by 45% to 26; howeve r, the differe nce in
means rose only 2% to 43 days.
This observe d decline in compan ies manufa cturing only one
device, minima l change in mean day differe nces, and decline in
signifi cance level was also observe d in 1981 and 1983. In 1982, the
signifi cance level again rose to 0.009 which seemed to be explain ed
by an increas e in time to equival ence over 19 81 for compan ies
manufa cturing only one device.
In 1984, there was a decline in days to equival ence for
compan ies manufa cturing one device and a slight increas e for those
manufa cturing more than one device; thus,

the reason for the

attainm ent of a non-sig nifican t level. In 1986, no decline was
seen, howeve r. The achieve d signifi cance level of O. 078 may be
explain ed by the small sample size during this year. Althoug h 1987
also had a small sample size, the increas e in days to equival ence
for compan ies manufa cturing one device was much more pronoun ced
when compare d to 1986 (12% vs. 7%).
Through out the years 1977 -

1987, the range of days to
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equival ence for compan ies manufa cturing more than one device was
124 in 1977 to 131 in 1987. Howeve r, the range for compan ies
manufa cturing only one device was 166 days in 1977 to 226 days in
1987.
Anothe r agency perspe ctive which provide d insigh t to the
attaine d signifi cance levels in 1984 and 1986 was the introdu ction
of more stringe nt regulat ory require ments during 1984 and 1986. The
Medica l Device Reporti ng (MDR) law was put into effect in late
1984. This law require d all compan ies to report all device defects
which may have had an adve=se effect on the health and safety of
the patien t. Never before had such reporti ng been require d nor in
such a structu red manner nor with such strikin g consequ ence. The
anticip ation and enactm ent of such a law may have neutra lized any
differe nce in days to equival ence for the two groups for this
compar ison.
Thus, the null hypoth esis was rejecte d at the .OS level for
all years other than 1984 and 1986. The number of days to
equival ence was depend ent on the number of devices a firm
manufa ctures.

The company charac teristic of manufa cturing one
device versus manufa cturing more than one device did seem to have

an impact on time to equival ence over time. Those compan ies that
manufa ctured more than one device accumu lated fewer days of time
to equival ence as compare d to compan ies who manufa ctured only one
device.
Hypoth esis 2.5. There is no differe nce between compan ies who
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r·eport using regulato ry affairs consul tants and companie s that
ti~n't

use

regulato ry

affairs

consulta nts

on

time

to

Table 9 below reflects the results of testing hypothes is

2.s

equivalenC""".

by years 1977 through 1987.

Table 9
Wilcoxon Scores (Rank Sums) for Variable DAYS
TO EQUIVALENCE Classifi ed by Variable RB6ULATORY CONSULTANT USE
Year

Class

H

Mean

1977

Yea

142

122.15

Ho

121

143.55

1978

1979

1980

1981

1982

1983

1984

1985

1986

1987

Yea

145

121.61

Ho

118

144.57

Yea

147

120.83

Bo

116

146.14

Ye&

178

128.38

Ho

85

139.58

Yea

186

131.00

Bo

77

134.40

Yes

189

130.80

BO

74

135.04

Yes

177

128.99

Bo

86

138.19

Yes

155

123.72

50

108

143.88

Yes

126

129.45

Bo

137

134.45

Yes

129

131.60

Ho

134

132.28

Yea

129

131.60

Ro

134

132.38

CBISQ

Prob>CBISQ

l

5.71

0.020•

l

6.02

0.014•

l

7.17

0.007•

l

1.24

0.264

l

0.11

0.742

l

0.16

0.685

l

0.85

0.357

l

4.47

0.034•

l

0.30

0.586

l

0.007

0.933

l

0.007

0.933

df

••Signific ant at 0.05 level.

Page 83

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Time to Equiv alenc e
From 1977 to 1982 the use of regul atory affai rs consu ltants
was on the inclin e. From 1983 to 1987, the use of consu
ltants
declin ed.
From 1977 to 1980 a stati stica lly signi fican t diffe rence was
found to exist betwe en group s at the .OS level . This signi fican
ce
level

progr essiv ely

decli ned

from

consu ltant use was the highe st.

1980

t.:iiL"o-~gh

198~,

when

In 1984, when consu ltant use

starte d to balan ce out with non-u se, a stati stica lly signi fican
t
ciffer ence ( p > 0.05) was detec ted again . Howe ver, as
the
discre pancy betwe en use and non-u se dimin ished from 1985 throu
gh
1987, so did the diffe rence in days to equiv alenc e.
Patte rns which emerg ed withi n the indus try and agenc y as
expre ssed earli er were seen here as well. In an effor t to
stay
comp etitiv e withi n the newly regul ated ma,ke tplace , the medic
al
devic e manu factur er broug ht in outsi de regul atory consu ltants
from
1977 throu gh 1982. This newly insti tuted workf orce had
a
stati stica lly signi fican t impac t on time to equiv alenc e in
1977.
This influe nce incre ased from 1978 throu gh 1979. In 1979, where
the
great est signi fican ce level was attain ed, it was appar ent that
the
use of outsi de regul atory consu ltants was produ cing a profo
und
impac t on time to equiv alenc e.
seen befor e, once the indus try acqui red inter nal regul atory
exper tise throu gh train ing and new emplo yees, use of consu
ltants
was less influ entia l. After 1979, FDA was perfe cting its train
ing
As

progra ms and disse minat ion of inform ation . Al thoug h consu ltant
use
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did

not

decline

from

1980

through

1S83,

no

statist ically

signifi cant differe nce in time to equival ence was detecte d. This
lack of signifi cance was possib ly due to consul tant activit ies
devoted

to

keeping

up

with

more

stringe ntly

imposed

older

regula tions. Wherea s, in 1984, when signifi cance was seen again,
consul tant use, al though on the decline , was being applied in
respons e to new regulat ions (e.g., MOR law).
In conclu sion, it seemed apparen t that early (1977 - 1979)
consul tant use may have contrib uted to reduced days to equival ence.
Albeit , as the number of days to equival ence increas ed and
consul tant use decline d, the impact on time to equival ence was less
measur able. In other words, early differe nces in time to
equival ence may have been depend ent on use of regulat ory affairs
consul tants. The more recent trend, howeve r, indicat ed
that days to equival ence was indepen dent of consul tant use.
Thus, the null hypoth esis was rejecte d at the .OS level of
signifi cance for years 1977 - 1979 and 1984.

Researc h Questio n Number 3
Is there a any differe nce between time to equival ence and
respon dent's (compa ny's) attitud es about selecte d charac teristic s
of the regulat ory process as having an impact on time to
equival ence?
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Since the assum ptions of norma lity for an ANOVA were not met
for this resear ch questi on, hypoth eses 3.1 throug h 3.5 were tested
via the Krusk al-Wa llis test. Tables 10 - 14 supply inform ation
relate d to these tests.
In Tables 10 - 14, the compa rison betwee n groups reflec· :.:ed
inform ation relate d to classe s or levels of the indepe ndent
variab le. Class 1 equals "Stron gly Agree ". Class 2 equals "Agree ".
Class 3 equals "No Opinio n". Class 4 equals "Disag ree". Class 5
equals "Stron gly Disagr ee".

Hypot hesis 3.1. There is no differ ence betwee n the compa nies
who percei ve FDA writte n commu nicatio n as having an impac t on
timely compl iance and compa nies that don't percei ve FDA
writte n co:mrm micatio n as having an impact on timely compl iance
on time to equiva lence.

Table 10 highli ghts the result s of testin g hypoth esis 3.1.
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Table 10
Wilco xon Score s (?.ank Sums) for Varia ble DAYS
TO EQUIVALENCE Class ~fied by Varia ble ATTITUDE
TO'WARD WRITTEN COM.MUNICATION WITH FDA
Class

N

Mean Score

Stron gly Agree

22

161.2 0

Agree

137

116.6 4

No Opini on

5

131.5 0

Disag ree

94

143.6 9

Stron gly Disag ree

5

205.1 0

Krusk al-Wa llis Test (Chi- Squar e Appro ximat ion)
CHISQ=lS.667 df=4

Prob> CHISQ=0.003

Since the calcu lated value of the test stati stic excee ded the
critic al value at the O. 003 level , th&re was a stati stica
lly
signi fican t di£ feren ce betwe en the vario us level s of agree
ment
regar ding writt en comm unicat ion with FDA and time to equiv alenc
e.
The

null

hypot hesis

was

rejec ted.

In

concl usion ,

the

differ ence in avera ge days to equiv alenc e for the five level
s of
agree! dent regar ding writt en comm unicat ion with the FDA
was
stati stica lly signi fican t at the 0.003 level . There was
a
diff~: rence in mea."l days to equiv alenc e betwe en compa nies
who
perce ived writt en comm unicat ion with FDA as havin g an impac
t on
timel y comp liance and compa nies who did not perce ive writt
en
Page 87

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Time to Equi valen ce
comm unica tion with FDA as havin g an impa ct on time ly comp
lianc e.
Revie w of Table 10 indic ated that those respo nden ts who
agree d
that writt en comm unica tion with FDA impa cted time to
equiv alenc e
had the lowe st mean time to eq-.ii valen ce ( 116 days) and
the grea test
number of respo nden ts (n = 137) •
The next high est group of
respo nden ts (n = 94) disag reed with the tene t that
writt en
commu..~ication impa cted time to equiv alenc e and thei r mean
time to
equiv alenc e was 131 days. Those respo nden ts who stron gly
disag reed
with the influ ence of writt en comm unica tion had the high
est mean
value of 205 days to equiv alenc e. It was inter estin g to
note that
those respo nden ts who stron gly agree d with this influ ence
had the
secon d high est mean time to equiv alenc e ( 161 days)
• This may
indic ate that exten sive writt en comm unica tion with FDA
resu lts in
delay s asso ciate d with nume rous chan nels of comm
unica tion,
inter facin g revie w bodi es, bure aucr atic leve ls, and the
logi stics
of gene ratin g and loggi ng offic ial comm unica tions with
FDA.
Hypo thesi s 3.2. There is no diffe renc e betwe en comp anies
who
perce ive FDA oral comm unica tion as havin g an impa ct on
time ly
comp lianc e

and

comp anies

that

don' t

perce ive

FDA

oral

comm unica tion as havin g an impa ct on time ly comp lianc e
on time
to equiv alenc e.

Table 11 high light s the resu lts of testi ng hypo thesi s
3.2.
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Table 11
Wilco xon Score s (Rank Sums) for Vari able DAYS
TO EQUIVALENCE Clas sifie d by Vari able ATTITUDE
TOWARD ORAL COMMUNICATION WITH FDA
Class

N

Mean Sccre

Stron gly Agre e

28

160.0 5

Agre e

154

129.0 0

No Opin ion

5

118.9 0

Disag ree

76

128.6 0

Stron gly Disa gree

0

000.0 0

Krus kal-W allis Test (Chi- Squa re Appr oxim ation )
CHISQ = 4.349

df=3

Prob > CHISQ = 0.226

Since the calcu lated value of the test stati stic
did not
excee d the criti cal value at the 0.05 leve l, there
was no
meas urabl e diffe renc e betw een the diffe rent leve ls
of agree ment
regar ding oral comm unica tion with FDA and time to equiv
alenc e.
Altho ugh over 69% of the respo nden ts were of the opin
ion that
oral comm unica tion with FDA did impa ct time to equiv
alenc e, there
did not appe ar to be a stati stica lly meas urabl e diffe renc
e in time
to equiv alenc e. It was notew orthy that those indiv
idua ls who
disag reed with this hypo thesi s had secon d lowe st mean
valu e. In
addi tion, those r.8sp onden ts with no opin ion abou t this
influ ence
on time to eqi~i valen ce had the lowe st mean days. This
findi ng was
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diffi cult to asses s due the low numbe r of respo ndent s in
this
categ ory.
The null hypot hesis was retain ed. Thus, the diffe rence in
avera ge days to equiv alenc e for the five level s of agree
ment
regar ding oral comm unicat ion with the FDA was not stati stica
lly
signi fican t diffe rent at the 0.05 level . There was no stati stica
lly
signi fican t diffe rence in mean days to equiv alenc e betwe en
those
compa nies who perce ived oral comm unicat ion with FDA has havin
g an
infl11 ence on timel y comp liance and those compa nies who did
not
perce ive

oral

comm unicat ion

as

havin g

an

impac t

on

timel y

comp liance .

Hypo thesis 3.3. There is no diffe rence betwe en compa nies who
perce ive the Offic e of Small Manu factur ers Assis tance (OSMA)
regul atory comp liance train ing as havin g an impac t on timel y
comp liance and compa nies who don't perce ive the OSMA
regul atory comp liance train ing as havin g an impac t on timel y
comp liance on time to equiv alenc e.
Table 12 has the resul ts of testin g hypot hesis 3.3.
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Table 12
Wilcox on Scores (Rank Sums) for Variab le DAYS
TO EQUIVALENCE Class ified by Variab le ATTITUDE
TOWARD REGULATORY TRAINING

Class

N

Mean Score

Strong ly Agree

27

137.05

Agree

158

128.99

No Opinio n

24

125.77

Disagr ee

53

141.34

Strong ly Disagr ee

1

125.00

Krusk al-Wa llis Test (Chi-S quare Appro ximati on)
CHISQ = 1.335

df=4

Prob> CHI~Q = 0.855

Since the calcul ated value of the test statis tic did not
exceed the critic al value at the 0. 05 level, there was no
statis ticall y measu rable differ ence betwee n the variou s levels of
agreem ent regard ing regula tory traini ng experi ence and time to
equiva lence.
Again , the major ity of the respon dents

(70%)

agreed that

regula tory traini ng did impact time to equiva lence, but the
differ ence in mean values were not statis ticall y signif icant. The
highes t mean values were record ed for those respon dents who were
of the opinio n that regula tory traini ng did not impac t time to
equiva lence (141 days).
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Due to the large numbe r of respo ndent s (n = 24) who had
no
opini ou about this influ ence, a 2x3 contin gency table
was
gener ated. A dicho tomou s categ ory of agree and disag ree
was
cross tabul ated with three level s of days (i.e. , 0-50, 50-10
0, and
great er than 100 days) . Those respo ndent s with no opini on
were
colla psed into the disag ree ca~eg c:ry to assur e a conse
rvativ e
inter preta tion of the resul ts. Table 13 prese nts the resul
ts of
that cross tabul ation . A non-s ignif icant resul t was achie ved
for
this test of diffe rence betwe en the obser ved numbe r and
the
expec ted numbe r of respo nses.

Table 13
Cross tabul ation of Varia ble DAYS TO EQUIVALENCE
by Varia ble ATTITUDE TOWARD REGULATORY TRAINING
Days to Bquival. em:e

Agree

n

Jlllgul.at ory

Q:.§.Q_

fil.::!.Q.2.

99

62

24

185

33.51

12.97

70.34

Ii 53.51

~

~

Disagree

n

41

27

10

78

I

52.56

34.62

12.82

29.66

n

140
\

89

53.22

33.84

CBISQ • 0.030

df•2

34

263

12.93
Prob > CBISQ • 0.985
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The

null

hypot hesis

was

retain ed.

In

concl usion ,

the

diffe rence in avera ge days to equiv alenc e for the five level
s of
agree ment regar ding regul atory train ing was not stati stica
lly
signi fican t at the 0.05 level . The colla psed cross tabul ation
was
also not signi fican t at the 0.05 level . It was appar ent that
the
diffe rence in time to equiv alenc e was not stati stica lly signi fican
t
with regar d to opini ons relate d to regul atory train
ing.
Conse quent ly, there was no stati stica lly signi fican t diffe rence
in
mean days to equiv alenc e betwe en compa nies who perce ived
OSMA
regul atory train ing as ha~·in g an influe nce on timel y comp liance
and
compa nies who did not perce ive OSMA regul atory train ing as havin
g
an influe nce on timel y comp liance .
Hypo thesis 3.4. There is no diffe rence betwe en compa nies who
perce ive havin g an in-ho use regul atory depar tment as havin g
an impac t on timel y comp liance and compa nies who don't
perce ive havin g an in-ho use regul atory depar tment as havin g
an impac t on timel y comp liance on time to equiv alenc e.
Table 14 highl ights the resul ts of testin g hypot hesis 3.4.
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Table 14
Wilco xon Score s (Rank Sums) for Varia ble DAYS
TO EQUIVALENCE Class ified by Varia ble
ATTITUDE TOWARD AN IN-HOUSE REGULATORY DEPARTMENT
Class

N

Mean Score

Stron gly Agree

82

127.1 5

Agree

174

134.5 3

No Opini on

6

118.2 5

Disag ree

1

171.5 0

Stron gly Disag ree

0

000.0 0

Krusk al-Wa llis Test (Chi-S quare Appro ximat ion)
CHISQ

=

0.993

df=3

Prob > CHISQ = 0.803

Since the calcu lated value of the test stati stic did not
excee d the criti cal value at the O. OS level , there
was no
stati stica lly signi fican t diffe rence betwe en the vario us level
s of
agree ment

regar ding

the

prese nce

or

absen ce

of

an

in-ho use

regul atory affai rs depar tment and time to equiv alenc e.
Altho ugh 97% of the respo ndent s agree d that an in-ho
use
regul atory depar tment impac ts time to equiv alenc e, no diffe
rence
in means was appar ent.

It was notab le that there was a large

diffe rence in mean days to equiv alenc e betwe en those that
agree d
and those that disag reed. Howe ver, the small numbe r of respo
ndent s
who disag reed (n = 1) made this comp arison quest ionab le.
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The

null

hypoth esis

was

retain ed.

In

conclu sion,

the

differ ence in averag e days to equiva lence for the five levels of
agreem ent regard ing in-hou se regula tory depart ments was not
statis ticall y signif icant at the 0.05 level. That is, there was no
statis ticall y signif icant differ ence in mean days to equiva lence
betwee n compa nies who percei ved the presen ce of an in-hou se
regula tory depart ment as having an influe nce on timely compl iance
and compa nies who did not percei ve having an in-hou se regula tory
depart ment as having an influe nce on timely compl iance.
Hypot hesis 3.5. There is no differ ence betwee n compa nies who
percei ve the use of outsid e regula tory affair s consu ltants as
having an impact on timely compl iance and compa nies that don't
percei ve the use of outsid e regula tory affair s consu ltants as
having an impact on timely compl iance on time to equiva lence.
Table 15 highli ghts the result s of testin g hypoth esis 3.5.
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Table 15
Wilco xon Score s (Rank Sums) for Varia ble DAYS
TO EQUIVALENCE Class ified by Varia ble ATTITUDE
TOWARD REGULATORY CONSULTANT USE

Class

Mean Score

N

Stron gly Agree

.4

138.5 5

Agree

158

123.3 4

No Opini on

64

131.4 8

Disag ree

16

177.4 4

Stron gly Disag ree

21

162.8 8

Krusk al-Wa llis Test (Chi-S quare Appro ximat ion)
CHISQ = 11.25

df=4

Prob> CHISQ = 0.024

Since the calcu lated value of the test stati stic excee ded the
critic al value at the 0.05 level , there was a stati stica
lly
signi fican t diffe rence betwe en the vario us level s of agreem
ent
regar ding the use of outsi de regul atory affai rs consu ltants
and
time to equiv alenc e.
Only 61% of the respo ndent s agree d that time to equiv alenc
e
was impac ted by use of outsi de regul atory consu ltants . Thirt
y-one
perce nt were of no opini on and 8% of the respo ndent s disag reed.
The
a ·erage mean value for those that agree d was 130 days. The avera
ge
mean value for those that c~s~g reed was 166 days.
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As with hypoth esis 3.3, a large portio n of the respon dents

were of no opinio n regard ing this influe nce on timely compl iance.
A 2x3 contin gency table was genera ted again with the no opinio
n
respon ses being collap sed into the disagr ee catego ry. Table 16
highli ghts the result s of this analy sis. Althou gh the chi-sq uare
statis tic was not statis ticall y signif icant at the 0.05 level, it
was notabl e that the percen tage of respon dents who disagr eed with
this influe nce was twice that of those that agreed when beyond 100
days to equiva lence, 18.81% and 9.26%, respec tively . This nr.Jnsignif icant findin g may be attrib uted to the conser vative ness of
collap sing the no opinio ns into the disagr ee catego ry.

Table 16
Cross tabula tion of Variab le DAYS TO EQUIVALENCE
by Variab le ATTITUDE TOWARD REGULATORY
CONSULTANT USE
Dll'fll to Zqui.Tale nca

Agree
C0Dsalta nt

~

51 - 100

n

91

56

15

162

I

56.17

34.57

9.26

61.60

49

33

19

101

I

48.51

32.67

18.81

38.40

n

140

I

53.22

33.84

CBISQ • 5.143

d1:•2

?!.QQ

1Jae

Disa51ree

n

89

34

263

12.93
Prob > CBISQ • 0.085
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Based

on

the

Krus kal-W allis

test

stat istic ,

the

null

hypo thesi s was rejec ted. In conc lusio n, the diffe renc
s in avera ge
days to equiv alenc e for the five leve ls of agree ment regar
ding use
of regu lator y affa irs cons ultan ts was sta~ istic ally sign
ifica nt at
the

O• 05

leve l.

Thus ,

there was

a

stati stica lly sign ifica nt

diffe renc e in mean days to equiv alenc e betw een comp
anies who
perce ived the use of outsi de regu lator y cons ultan ts
as havin g an
impa ct on time ly comp li&nc e and comp anies who did not
perce ive the
use of outsi de regu lator y cons ultan ts as havin g an impa
ct on time ly
comp lianc e.

Rese arch Ques tion Number 4
What

comb inatio n

of

indep ende nt

varia ble

meas ures

best

pred icts time to equiv alenc e?
The testi ng of resea rch ques tion numb er 4 invol ved looki
ng at
comb ined indep ende nt varia bles and how t.hose comb inatio
ns pred icted
time to equiv alenc e. Up to this poin· t conc entra tion
had been on
pred ictin g time to equiv alenc e based on the follo wing
indep ende nt
varia bles: numb er of year s manu factu ring medi cal devic
es, number
of empl oyees in the orga nizat ion, and numb er of empl
oyees in the
regu lator y depa rtmen t. The ques tion still rema ined as
to what othe r
varia bles may have also effec ted time to equiv alenc e.
Since this
mode l

invol ved

mult iple

indep ende nt

varia bles,

a

mult iple

regre ssion pred ictio n equa tion with conve:r'i::ed beta
weig hts were
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calcu lated .
There were twelv e indep enden t varia bles in this equat ion,
Xi- •• X12 • They were the follow ing: numbe r of years manu factur
ing
medic al devic es (YEARS), numbe r of emplo yees in the organ izatio
n
in 1987 (EMP087), prese nce or absen ce of a regul atory depar
tment
in 1987 (REG87), numbe r of emplo yees in that regul atory depar
tment
in 1987 (EMPR87), regul atory train ing exper ience in 1987 (TRN8
7),
numhe r of devic es manu factur ed in 1987 (DEV87), use of regul
atory
consu ltants in 1987 (CON87), opini on about the impac t on time
to
equiv alenc e with regar d to oral comm unicat ion with FDA (OCOM
M):
writt en comm unicat ion with FDA (WCOMM), regul atory train
ing
(TRAI N),

in-ho use

regul atory depar tment

(INRE G),

and outsi de

regul atory consu ltants ( OUTREG) • The follow ing estim ated regre
ssion
predi ction equat ion was formu lated:

where b 11 b 2 • • • • b 12 estim ate the regre ssion coeff icien ts

.B 1 ,

Table 17 below highl ights the resul ts of this test.
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Table 17
Model Relat ing Varia ble DAYS TO EQUIVALENCE to
Multi ple Indep enden t Varia bles
Multi ple R

=

.787

varia ble

df

Beta Weigh ts

p-val ue

DAR$

12

-0.261

O.146

BJIP087

12

0.113

0.413

BMPR87

12

0.001

0.987

RBG87

12

-0.213

0.207

TRH87

12

-0.036

0.863

DBV87

12

0.109

O.SC6

COB87

12

-0.392

0.115

OC0MM

12

0.652

0.021•

lfCOMM

12

0.097

0.718

TRAIN

12

-0.242

0.123

IHRBG

12

0.176

0.559

OtrnmG

12

0.701

0.001•

• Signific ant at 0.05 level.

Table 17 repre sents the calcu lated beta weigh ts and signi fican
ce
level s for each varia ble. The beta weigh ts were then inser ted
into
the multi ple regre ssion predi ction equat ion as displ ayed below
. The
beta weigh ts indic ated which varia bles contr ibute d the most
to the
predi ction of days to equiv alenc e, the depen dent varia ble.
The
equat ion was:
DAYS '1'0 BQOIVALEHCE • -O.261(Y BARS) + 0.113(BN P08?)

+

0.001(EH PR87) + -0.213(R BG87) + -0.036( ~87) + 0.109(I>BV87)
+
0.392(CO B87) + 0,652(0COMH) + 0.097(WCOMN) + -0.24 2(~)
+
0.176(:n nmG) + 0.701(00 TRBG).
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The numb ers in the equa tion are inter prete d as follo ws:
b 1 = -0. 2 61 was the estim ate of the relat ive pred ictio n
weig ht
for the varia ble YEARS MANUFACTURING MEDICAL DEVICES~
b 2 = 0 .125

was the estim ate of the relat ive pred ictio n weig ht
for the varia ble NUMBER OF EMPLOYEES IN THE ORGANIZAT
ION.

b 3 = 0.001 was the e&tim ate of the relat ive pred ictio
n weig ht
for the varia ble NUMBER OF EMPLOYEES IN THE REGUL
ATORY
DEPARTMENT.

b,

= -0. 392 was the estim ate of the relat ive pred ictio n weig ht

for the varia ble IN-HOUSE REGULATORY DEPARTMENT.
Estim ates

were

supp lied

for

the

rema ining

popu latio n

param eters (b5 ••• b 12 ) as indic ated in the equa tion abov
e.
Of

i.mpo~~ance

were

the

relat ive

pred ictio n

value s

and

signi fican ce prob abili ties for the twelv e estim ates in
the mult iple
regre ssion pred ictio n equa tion. The relat ive pred ictio
n value s
indic ated which pred ictio n varia bles cont ribut ed the
most to
succ essfu l pred ictio n. The sign ifica nce prob abili ties
(p-va lues)
indic ated if the pred ictor varia bles were sign ifica ntly
diffe rent
from zero.
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Revie w of Table 17 indic ates that the respo nden t's perce
ived
influ ence of outsi de cons ultan t use on time ly comp lianc
e and the
influ ence of oral comm unica tion ~ith FDA en time ly comp
lianc e were
the best relat ive pred ictor s of days to equiv alenc e. Actu
al use of
outsi de regu lator y cons ultan ts and numb er of years manu
factu ring
medi cal devic es appe ared to be secon dary cont ribut
ors to the
succ essfu l pred ictio n of days to equiv alenc e.
The signi fican ce prob abili ties for the respc •nden t's attit
udes
towa rd use of outsi de regu lator y cons ultan ts and oral comm
unica tion
with FDA gave adeq uate evide nce of the stati stica lly
sign ifica nt
effe ct of these varia bles on pred ictin g time to
equiv alenc e.
Furth ermo re, the p-va lue at the 0.05 leve l indic ated
with 95%
con£ idenc e that these parti cula r pred ictor varia bles
assi st in
decre asing the diffe renc e betwe en the pred icted
and actua l
crite rion score s.
In conc lusio n,

two of the twelv e varia bles were prim ary
cont ribut ors to succ essfu l pred ictio n and two addi tiona
l varia bles
may be cons idere d secon dary cont ribut ors to succ essfu l
pred ictio n.
Opin ions abou t the impa ct of oral comm unica tion ..,i.th
FDA on time
to equiv alenc e and opini ons abou t the impa ct of outsi de
regu lator y
cons ultan t use on time to equiv alenc e seeme d to best pred
ict time
to equiv alenc e. Actu al use of outsi de regu lator y cons
ultan ts and
the m1 mher of years a company has been manu factu ring
medi cal
devic es were secon dary pred ictor s of ti.me to eq-~i valen
ce.
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Some sugges ted conclu sions were: 1) regula tory manag ers who
percei ve outsid e consu ltant use as being influe ntial on time to
equiva lence :may expec t to have lower mean days to equiva lence than
those manag ers who disagr ee with this percep tion in light of the
result s of testin g hypoth esis 3. 5: 2) regula tory manag ers who
believ e that oral commu nicatio n with FDA does influe nce timely
compli ance may expec t higher mean days to equiva lence than those
manag ers that do not agree with this tenet in light of the result s
of testin g hypoth esis 3.2.

Resear ch Questi on Number 5
What variab les appear to have an impact on time to equiva lence
as percei ved by the company respon dent? This resear ch questi on
relate s to questi ons numbe r 4 and 10 on the questi onnai re.
Respon dents were asked in Questi on Number 4 their opinio n
about the influe nce of the FDA review proces s on produ ction costs.
Appro ximate ly

half

(54.7% )

of

the

respon dents

stated

that

produ ction costs were influe nced by the FDA review proces s. When
examin ing this same variab le within specif ied subgro ups, this same
distri bution was approx imated . For examp le, among compa nies
manuf acturin g more than one device in 1987, 54% stated there was
an influe nce on produ ction costs. For compa nies who receiv ed
regula tory traini ng in 1987, the percen tage was 54%. For compa nies
who had regula tory depart ments in 1987, it was 51%. Howev er, among
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compan ies who employe d regulat ory consul tants in 1987, 76% stated
produc tion costs were influen ced by the review process . Wherea s,
among compan ies who did not use outside consul tants, only 34% felt
produc tion costs were influen ced by the review process .
As a result, for the study group as a whole and within many
subgrou pings, opinion s were evenly divided with regard to the

influen ce of the FDA review process on produc tion costs. Howeve r,
compan ies that were subgrou ped by outside consul tant use did not
follow this pattern . Althoug h compan ies using outside regulat ory
consul tants benefit ed from this utiliza tion, (i,e., less time to
equival ence in years immedi ately followi ng the enactm ent of a new
regulat ion - Hypoth esis #2.5), it seemed apparen t that it was the
opinion of compan ies using outside regulat ory consul tants that
produc tion costs were impacte d by the
contra st,

many

of

the

compan ies

that

FDA

review process .

did

not

use

In

outside

consul tants, did not feel produc tion costs were influeu ced by the
review process .
With regard to Questio n Number 10 on the survey, 81% of the
respond ents indicat ed other things or entitie s which were not
directl y address ed on the questio nnaire that may impact time to
equival ence.

Table

18

below

lists

those

respons es

and

the

percent age of respond ents who emphas ized them.
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Table 18
Frequ ency Distr ibuti on of Enti ties
Impa cting Vari able TIME TO EQUIVALENCE
Resp onse

Perc ent

1) Chan ging Regu latio ns

26

2) Chan ges in FDA Polic y

10

3) Lawy ers and FDA Revie w Pane l

10

4) Limi ted FDA Staf f

10

5) Prop erly Prep ared Subm ission s

10

6) Lack of FDA Fund ing

4

7) Pre- clini cal Expe rtise

4

8) FDA Budg et Probl ems

4

9) Rapp ort with FDA

3

10) Devi ce Comp lexity

2

11) Othe r

~

lla) FDA Over load
llb) R

&

Tota l

= 100

D Qual ity

llc) FDA Revi ewer 's Know ledge Leve l
lld) Bind er Qual ity
lle) Poli tical Press ure on FDA
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SUMMARY

The chap ter prese nted resu lts on the impa ct of fede ral
socia l
regu latio ns upon the time requ ired to estab lish equiv
alenc e for a
medi cal devic e with in the ortho paed ic medi cal devic
e indu stry.
Means and stand ard devi ation s for time to equiv alenc
e with in
spec ified subgr oups were calcu lated . Comp arison s of mean
s relat ed
to company char acte risti cs were made . Regr essio n coef
ficie nts and
Krus kal-W allis chi-s quar e stati stics were calcu lated . Most
relev ant
resu lts of these comp utatio ns are summ arized in the
follo wing
parag raphs .

Rese arch Ques tion One
A total of two hund red and sixty three respo nses was inclu
ded
in the data anal ysis. The impa ct of fede ral socia l regu
latio ns upon
time to equiv alenc e was exam ined by regre ssing three
indep ende nt
varia bles on one depen dent varia ble, time to equiv alenc
e.
The first indep ende nt varia ble was the numb er of years
a
company had been manu factu ring medi cal devic es. This impa
ct was in
a nega tive direc tion. A stati stica lly meas urabl e diffe
renc e was
detec ted at the O. 05 leve l. A relat ions hip was found
to exis t
betwe en the numb er of years manu factu ring and time to
equiv alenc e.
As the numb er of year s a comp any manu
factu red medi cal devic es
incre ased , there was a pred ictab le decre ase in the amou
nt of time
requ ired to get a medi cal devic e throu gh the FDA revie w
proce ss and
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estab lish equi· llenc e.
The secor . ... indep ende nt varia ble was the numb er of empl
oyees
in the orga nizat ion. The relat ions hip of this varia ble
with time
to equiv alenc e was evalu ated over time from 1977
to 1987 . A
posi tive relat ions hip was found to exis t from 1978 throu
gh 1982 .
the numb er of empl oyees in a company incre ased , so
did the
numb er of days requ ired to estab lishe d equiv alenc e durin
g these
year s.
As

A stati stica lly sign ifica nt diffe renc e was asce rtain ed
at the
0.05 level from 19713 throu gh 1982 , while no pred icabl e
relat ions hip
seeme d to exis t in 1977 , nor from 1983 throu gh 1987 . The
reaso n for
this patte rn poss ibly rests with the comb ined respo nse
of FDA and
indu stry to the enact ment of the 1976 Medi cal Devi ce
Amendments.
This repre sente d a matu ratio n proce ss which evolv ed over
time.
The third indep ende nt varia ble was the numb er of empl oyees

in
the regu lator y depa rtmen t. This relat ions hip was also
evalu ated
over time. No stati stica lly sign ifica nt diffe renc e was
achie ved for
any year from 1977 throu gh 1987 . Altho ugh no stati
stica lly
sign ifica nt diffe renc e

was

appa rent,

howe ver,

the

numb er of

empl oyees in the regu lator y ~apa rtmen t did seem to have
a nega tive
impa ct on time to equiv alenc e.
Rese arch Ques tion Two
The impa ct cf ~pcc ified company char acte risti cs on
time to
equiv alenc e was exam ined. Five indep ende nt varia bles were
meas ured.
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Those

variabl es

or

charac teristic s

were:

class

of

device

manufa ctured, in-hous e regulat ory departm ent, regulat ory trainin g,
number of devices manufa ctured, and use of out-of- house regulat ory
consul tants. All variab les, but class of device, were evaluat ed
over time, 1977 through 1987. A total of 263 respons es were
include d in the data analys is.
For the first indepen dent variab le, class of device based on
the associa ted degree of risk, the chi-squ are statist ic was not
statist ically signifi cant at the 0.05 level. In other words, time
to equival ence seemed to be indepen dent of the class of device
manufa ctured.
For the second indepen dent variab le,

in-hous e regulat ory

departm ent, the chi-squ are statist ic was found to be statist ically
signifi cant at the 0.05 level in 1979 only. Time to equival ence was
impacte d by the presenc e of an in-hous e regulat ory departm ent in
1979, but not from 1977 through 1978, nor from 1980 through 1987.
The third indepen dent variab le, regulat ory trainin g, was found
to impact time to equival ence in 1979 and 1980 only. The chisquare statis~ ic reveale d a statist ically measur able differe nce in
time to equival ence for these years, but not from 1977-19 78, nor
1981 through 1987. Thus, those compan ies who receive d regulat ory
trainin g in 1979 and 1980 were found to have a differe nce in time
to equival ence at the O.OS signifi cance level as compare d to
compan ies who did not experie nce regulat ory trainin g in 1979 and
1980.
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The fourt h indep enden t varia ble, numbe r of medic al devic es
manu factur ed, influe nced time to equiv alenc e for all years
excep t
1984 and 1986. The chi-s quare stati stic detec ted a stati stica
lly
measu rable differ ence at the 0.05 level in time to equiv alenc
e for
all years but 1984 and 1986. Aside from 1984 and 1986, compa
nies
who manu factur ed more than one devic e requi red notab ly fewer
days
to estab lish equiv alenc e than compa nies that manu factur ed only
one
devic e.
For the

fifth

indep enden t varia ble,

use

of

an outsi de

regul atory consu ltant had a stati stica lly signi fican t impac
t on
time to equiv alenc e from 1977 throu gh 1979, and then again in
1984.
No diffe rence was detec ted from 1980 throu gh 1983, nor after
1984.
The chi-s quare stati stic was stati stica lly signi fican t at the
0.05
level for 1977, 1978, 1979, and 1983 only. Time to equiv
alenc e
seeme d to be depen dent on outsi de consu ltant use for these
years
alone .

Resea rch Quest ion Three
Respo ndent s

attitu des

about

selec ted

attrib utes

of

the

regul atory proce ss and their impac t on time to equiv alenc
e were
ex~in ed. There were 263 respo nses in the data analy sis.
Five
attrib utes or indep enden t varia bles were speci fied. They were
the
follow ing: oral comm unicat ion with FDA, writt en comm unicat ion
with
FDA, regul atory train ing, in-ho use regul atory depar tment , and
outof-ho use regul atory consu ltant use.
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The chi-sq uare statis tic was statis ticall y signif icant at the
0.05 level for writte n commu nicatio n with FDA and use of outsid e
consu ltants only. No statis ticall y signif icant differ ence in class
means was detect ed for oral commu nicatio n with F~":.. regula tory
traini ng, nor in-hou se regula tory depart ment.
Thus, mean values

for those respon dents who

agreed that

writte n commu nicatio n and use of outsid e consu ltants impact s time
to equiva lence were statis ticall y differ ent from those respon dents
who disagr eed with this tenet. Mean values were signif icantl y lower
for the respon dents who agreed . One reason for this findin g may be
the

associ ation

of

regula tory

compl iance.

Compa nies

consu ltants

into

compl iance
qualit y

introd uce

their organ izatio n

activ ities

contr ol,).

who

profes sional s

(i.e.,

FDA

regula tory
also

is

regula tory

profes sional

introd uce

docum entatio n,

inspec tion

with

increa sed

record

emine nt

if

keepin g,

compl iance

activi ties are not docum ented and submi tted to FDA. In conce rt, FDA
review of medic al device s for substa ntial equiva lence is
facili tated and possib ly reduce d in time if the agency 's
requir ement s are fully met on the first submi ssion.
Howev er,

the

above resul t.s

were suspe ct based upon the

measur ement proces s. There was some concer n with the reliab ility
of the measur ement device relati ~e to the design of the questi on
items on the questi onnai re. Althou gh the coeffi cient of stabil ity
was satisf actory , the test-r etest reliab ility proces s had a small
number of partic ipants (n = 4). Addit ionall y, questi ons #5 - #9
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provi ded possi ble evide nce for the prima cy effec t. Items prese
nted
early in the list of optio ns were dispr oport ionat ely likel y
to be
cited among the favor ed optio ns. Conse quent ly, Quest ions IS 9 may
not have elici ted relia ble answe rs.
Resea rch Quest ion Four
The

impac t

of

feder al

socia l

regul ation s

on

time

to

equiv alenc e was measu red by evalu ating the combi ned influe nce
of
all indep enden t varia bles diffe renti ated in Resea rch Quest ions
One
throu gh Three . A total of two hundr ed and sirty three respo nses
was
inclu ded in the analy sis. This equat ion was formu lated to determ
ine
which popul ation param eters which were conve rted to beta weigh
ts
best precH cted time to equiv alenc e.
Thra .mult iple regre ssion predi ction equat ion produ ced beta
weigh t estim ates which were stati stica lly signi fican t at the
0.05
level for the opini ons about oral comm unicat ion with FDA
and
opini ons about use of outsi de regul atory consu ltants . Thus,
as
opini ons about oral comm unicat ion with FDA and its impac t on
time
to equiv alenc e shifte d from agree ing to disag reein g, there
was a
corre spond ing incre ase in days to equiv alenc e. And, as opini
ons
about outsi de consu ltant use and its impac t on time to equiv
alenc e
shift ed from agree ing to disag reein g, there was a predi
ctabl e
incre ase in days to equiv alenc e.
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Researc h Questio n Five
This descrip tive analysi s accumu lated respon dent's comments
about additio nal things not directl y address ed on the surv~y
questio nnaire which the respond ent though t influen ces time to
equival ence. A total of 263 respons es was include d in the analys is.
Eighty one percen t ( n = 213) of the respond ents provide d
additio nal entitie s which they though t impacte d the time require d
to get a medica l device through the review process and onto the
market . Sixteen general catego ries were referen ced by the
respond ents. The respond ents noted changin g regulat ions as
impacti ng time to equival ence most often (26%). The bulk of the
other comments were represe nted by the followi ng catego ries:
changin g FDA policy, lawyers and FDA review panel, limited FDA
staff, and properl y prepare d submis sions.
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Chapt er V

SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS

This chapte r presen ts an overvi ew of the study on federa l
social regula tions' impac ts on time to equiva lence in the
orthop aedic medic al device indust ry. The first sectio n is a review
of preced ing chapte rs, includ ing discus sion of the resear ch proble m
and approa ch, summary of releva nt resear ch litera ture, method , and
findin gs.

The conclu sion sectio n relate s findin gs to select ed
litera ture, e.~lua tes the resear ch and discus ses its implic ations .
The final sectio n makes recomm endatio ns for future study.

Summary
The Resear ch Proble m
Resear ch was condu cted to evalua te federa l social regula tions
and their impac t upon the time requir ed to get a medic al device
throug h the

FDA

review proces s and onto the marke t. Govern ment

regula tion of busine ss can be divide d into two basic catego ries:
econom ic and socia l. The purpos e of the study was to invest igate
the degree and nature of impac t, due to compl iance with differ ent
catego ries of the 1976 Medic al Device .Amendment, on the ti:::s to
equiva lence for compa nies with specif ied chara cteris tics and as
percei ved by the compa ny's regula tory affair s manag er.
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Speci fically ,

the

resear ch

was

design ed

to

answe r

the

devote d

to

follow ing resear ch questi ons:
1.

What

is

the

relati onshi p

betwee n

time

establ ishing an FDA dispo sition of substa ntial equiva lence for an
orthop aedic medic al device and relate d costs and resour ce
consum ption?
2.

Is there any differ ence betwee n respon dents (comp anies)
who posses s or do not posses s certai n identi fie& chara cteris tics
and time requir ed to estab lish equiva lence?
3.

Is there a any differ ence betwee n time to equiva lence and
respon dent's (comp any's) attitu des about select ed chara cteris tics
of the

regula tory proces s

as

having

an

impac t

on

time

to

eq-11ivalenc e?
4.

What combi nation of indepe ndent variab le measu res best
predic ts time to equiva lence?
5.

What variab les appea r to have an impac t on time to
equiva lence as percei ved by the company respon dent?
The Resear ch Appro aches
Approa ch I
The first level of analys is dealt with Resear ch Questi on
Number 1. The resear ch approa ch was a descr iptive -corre lation al
survey . Its purpos e was to determ ine the relati onshi p betwee n three
chara cteris tics of the orthop aedic medic al device manuf acturin g
company and time to equiva lence.
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Appro ach II
The secon d phase of the analy sis addre ssed Resea rch Quest ions
2 and 3. This analy sis compa red 2 to 5 level s of 10 indep enden
t
varia bles with one indep enden t varia ble, 'time to equiv alenc e.
Since
all comp arison s invol ved two or more group s and did not meet
the
assum ptions assoc iated with one-w ay analy sis of varia nce (ANOV
A),
the non-p arame tric analo gue Krusk al-Wa llis Test was utiliz
ed to
detec t diffe rence s betwe en group s or indep enden t varia ble level
s.
Appro ach III

The third metho d invol ved the developmeD.t of a multi ple
regre ssion predi ction equat ion with regre ssion coeff icien ts
and
beta weigh ts for all study varia bles on time to equiv alenc e.
This
was done in an effor t to detec t which varia bles best predi cted
time
to equiv alenc e.
Appro ach IV
This fourt h level of analy sis was prima rily descr iptiv e. It
addre ssed inform ation suppl ied throu gh quest ions 4 and 10 on
the
quest ionna ire. These quest ions reque sted the respo ndent suppl
y
opini on inform ation . This yield ed data which was quali tativ
e in
natur e and nomin al on type.
Crite ria for Data Sourc es
Sever al crite ria were used to selec t data sourc es and inclu de
the follow ing:
Page 115

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Time to Equival ence
Criteri a 1. Documents have to be related to orthopa edic medica l
device firms in the United States.
Criteri a 2. Selecte d device catego ries have no less than ten
devices manufa ctured between 1976 and 1988.
Criteri a 3. Selecte d firms have a regulat ory affairs departm ent and
manage r or some person respon sible for regulat ory affairs .
Criteri a 4. The person within each firm to whom the reques t for
data was address ed was the regulat ory affairs manage r or person
respon sible for filing SlO(k)s .
Review of Selecte d Literat ure
The role of governm ent had been primar ily to suppor t the
busines s system in its role of econom ic leaders hip and to mediate
between busines s and society . Govern ment's role had changed from
judging how well busines s perform ed its social respon sibiliti es to
defirtin g what these respon sibiliti es

should be.

The role of

governm ent was enlarge d to include a regulat ory functio n. A wave
of legisla tive regulat ion of busines s followe d. The rapid expansi on
of

governm ent

control s

had

been

associa ted

with

a

growing

dissati sfactio n with the affects of regulat ions.
Two widely accepte d divisio ns of federal governm ent regulat ion
were econom ic and social regulat ion. Govern ment's basic reform
strateg y had animate d the growth of federal protec tive regulat ory
program s and had created a series of regulat ory agenci es, all for
the

purpose

of

betteri ng

and

improv ing,

both

sociall y

and
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econ omic ally, the oper ation of busin ess and indu stry.
Both types
of regu latio ns cost , as well as bene fit, indu stry and
socie ty.
Weidenbaum (1977 ) iden tifie d expa nsion s of socia l
regu latio ns,
parti cula rly the six areas of job safet y, traff ic safe
ty, consu mer
prod ucts, perso nnel justi ce, consu mer finan ce, and envir
onme ntal.
Diffe rent regu lator y agen cies have creat ed guid eline
s for these
areas of socia l regu latio n.
Soci al regu latio n of the medi cal indu stry was first intro
duce d
in 1938 throu gh the Fede ral Food , Drug , and Cosm etic Act.
Prem arket
appro val for a medi cal devic e was first requ ired
in the late
1960 's. The enact ment of 28 bills betwe en 1965 and 1975
culm inate d
with the enact ment of the Medi cal Devic e .Amendments of
1976 .
In addi tion to the medi cal devic e indu stry, six
curre nt
resea rch

studi es

Rese arch

appro aches

with in

regu lated

were

comp ared

indu strie s
with

were

socia l

and

revie wed.
econo ~ic

prof itabi lity as the focus of the inve stiga tions .
Metho d
A desc riptiv e-com parat ive resea rch appro ach was cond ucted
to
exam ine the relat ions hip and diffe renc es betw een elem
ents of the
indep ende nt varia bles, company char acte ristic s and opin
ions, and
the depen dent varia ble,

time to equiv alenc e.

Desc riptiv e and

infer e~tia l stati stica l data , char acter izing varia ble relat
ions hips
and diffe renc es, were obtai ned throu gh the use of a maile
d surve y
colle cting factu al and opin ion data from a geog raph icall
y dispe rsed
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popu lation

of

ortho paedi c

medic al

devic e

manu factu rers.

A

resea rcher -desig ned quest ionna ire was used to colle ct data.
A
descr iptive -com parat ive appro ach was used for data analy sis.
Colle ction of Data
Data sourc es for the study were small and large ortho paedi c
medic al devic e manu factur ers from all over the U.S. Firms
were
selec ted from the SlO(k ) Regis ter, which liste d all SlO(k ) devic
e
subm ission s from 1976 to 1987. There were 263 usabl e respo nses
from
firms repre sentin g 27 diffe rent devic e categ ories .
The resea rcher -desig ned instru ment consi sted of a lette r of
trans mitta l and a quest ionna ire compo sed of three data colle
ction
pages with instru ction s.
After meeti ng crite ria for data sourc es, steps were taken to
imple ment data colle ction . The quest ionna ire was maile d to
small
and large firms selec ted from the 510lk ) Regis ter. Respo nses to
the
quest ions were comp iled on an indiv idual basis . A total of
106
quest ionna ires with self-a ddres sed envel ops was maile d.
This
proce ss resul ted in a 23% retur n rate. Those respo ndent s who
did
not retur n the maile d surve y initi ally were then surve yed via
the
teleph one. These two combi ned techn iques produ ced a total
of 39
compa nies with a 47.5% retur n rate.
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Analv sis of Data
Descr iptive -comp arativ e statis tics were used to answer the
resear ch questi ons. Standa rd measu r~s of centra l tenden cies
compr ising means and standa rd deviat ions were used to descri be
relatio nship s and differ ences betwee n variab les. Analys es for the
impact of the indepe ndent variab les upon the depend ent variab le,
time to equiva lence, were perfor med. Compa risons of means relate d
to company chara cteris tics were made. Regre ssion coeffi cients , beta
weigh ts and Krusk al-Wa llis chi-sq uare statis tics were calcul ated.
Findin gs
Resear ch Questi on One asked what was the relatio nship betwee n
time devote d to establ ishing an FDA dispo sition of substa ntial
equiva lence for an orthop aedic medic al device and relate d costs and
resour ce consum ption.
Hypot hesis 1.1. The first indepe ndent variab le was the numbe r
of years a compan y had been manuf acturin g medic al device s. This
impact was in a negati ve direct ion. A statis ticall y signif icant
di£ ferenc e was detect ed at the O. OS level. A relatio nship was found
to exist betwee n the numbe r of years manuf acturin g and time to
equiva lence.

the numbe r of years a compan y manuf acture d medic al
device s increa sed, there was a predic table decrea se in the amoun t
As

of time requir ed to get a medic al device throug h the
proces s and estab lish equiva lence.

FDA

review
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Hypot hesis 1. 2. The second indepe ndent variab le was the number
of employ ees in the organ izatio n. The relati onshi p of this variab le
with time to equiva lence was evalua ted over time from 1977 to 1987.
Positi ve relatio nship s were found to exist from 1978 throug h 1982.
As the numbe r of employ ees in a compan y increa sed, so
did the
number of days requir ed to establ ish equiva lence during these
years.
A statis ticall y signif icant differ ence was ascert ained at the
0.05 level from 1978 throug h 1982, while no predic able relatio nship
seemed to exist in 1977, nor from 1983 throug h 1987.
A ration ale for this result may be found in the combin ed
respon se of FDA and indust ry to the enactm ent of the 1976 Medic al
Device Amendments. The years immed iately follow ing the enactm ent
brough t about many change s in person nel and resour ce consum ption
for both the agency and indust ry. As years passed the FDA review
proces s became more compe tent and sophi sticat ed. Compa nies employ ed
increa singly
compl iance
satura ted

more

profes sional s

stipul ations .
depart ments

However,

were

not

to

meet

the

compa nies
produc ing

increa sed
discov ered

reduce d

time

FDA
that
to

equiva lence.
Hypot hesis 1.3. The third indepe ndent variab le was number of
employ ees in the regula tory depart ment. This relatio nship was also
evalua ted over time. No statis ticall y signif icant differ ence was
achiev ed for any year from 1977 throug h 1987. Althou gh no
statis ticall y signif icant differ ence was appare nt, the number of
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employ ees in the regula tory depart ment did seem to have a negati ve
impact on time to equiva lence.
Resear ch Questi on Two asked if there lA.-ere any differ ences
betwee n respon dents (comp anies) who posses s or do not posses s
certai n identi fied chara cteris tics and time requir ed to establ ish
equiva lence.
Hypot hesis 2.1. For the first indepe ndent variab le, class of
device based on the associ ated degree of risk, the chi-sq uare
statis tic of 0.224 was not statis ticall y signif icant at the 0.05
level. In other words, time to equiva lence seemed to be indepe ndent
of the class of device manuf acture d.
Hypot hesis 2.2. For the second indepe ndent variab le, in-hou se
regula tory depart ment, the chi-sq uare statis tic of 4.11 was found
to be statis ticall y signif icant at the 0.05 level in 1979 only.
Time to equiva lence was impac ted by the presen ce of an in-hou se
regula tory depart ment in 1979, but not from 1977 throug h 1978, no~
from 1980 throug h 1987.
Hypot hesis 2.3. The third indepe ndent variab le, regula tory
traini ng, was found to impac t time to equiva lence in 1979 and 1980
only. The chi-6q uare statis tic of 7.04 in 1979 and 1980 reveal ed
a statis ticall y measu rable differ ence in time to equiva lence for
these years, but not from 1977-1 978, nor 1981 throug h 1987. Thus,
those compa nies who receiv ed regula tory traini ng in 1979 a..~d 1980
were found to have a differ ence in time to equiva lence at the 0.05
signif icance level as compa red to compa nies who did not experi ence
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regulat ory trainin g in 1979 and 1980.
Hypoth esis 2.4. The fourth indepen dent variab le, number of
medica l devices manufa ctured, influen ced time to equival ence for
all years except 1984 and 1986. The chi-squ are statist ic detecte d
a statist ically measur able differe nce at the 0.05 level in time to
equival ence for all years but 1984 and 1986. The chi-squ are
statist .ic of 11.60 from 1977 through 1979 was notewo rthy. Aside
from 1984 and 1986, compan ies who manufa ctured more than one device
require d notably fewer days to establi sh equival ence than compan ies
that manufa ctured only one devi~c"
Hypoth esis 2.5. For the fifth indepen dent variab le, use of an
outside regulat ory consul tant had a statist ically signifi cant
impact on time to equiva lence from 1977 through 1979, and then
again in 1984. No differe nce was detecte d from 1980 through 1983,
nor after 1984. The chi-squ are statist ic for 1977 ( 5 .17), 1978
(6.02), 1979 (7.18) and 1983 (4.47) was statist ically signifi cant
at the 0.05 level. Time to equival ence seemed to be depend ent on
outside consul tant use for tnese years alone.
Researc h Questio n Three asked if there were any differe nces
between time to equival ence and respon dent's (compa ny's) attitud es
about selecte d charac teristic s of the regulat ory process as having
an impact on time to equiva lence.
Hypoth esis

3. 1.

The

first

indepen dent variab le,

written

conanun ication with FDA, was measur ed. The chi-squ are statist ic of
15.67 was statist ically signifi cant at the 0.003 le~el indicat ing
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that those respo ndent s who agree d with the tenet that writt
en
cODDDUnication with the FDA has an impac t on time to equiv alenc
e had
a signi fican tly lower mean days to eq-.iivalen ce than those
that
disag reed with this posit ion.
Hypo thesis

3.2.

The

secon d

indep enden t

varia ble,

oral

comm unicat ion with FDA, was evalu ated. No stati stica lly signi
fican t
differ ence was detec ted in mean respo nses to this varia ble.
The
numbe r of days requi red to get a devic e throu gh the FDA
review
proce ss seeme d to be indep enden t of respo ndent s' opini ons
about
oral comm unicat ion with FDA.
Hypo thesis 3 • 3 • The third indep enden t varia ble, opini ons about
regul atory train ing, was evalu ated with regar d to time
to
equiv alenc e. The diffe rence in mean days to equiv alenc
e for
respo ndent s who agree d or did not agree that regula to:?:'y train
ing
impac ted time to equiv alenc e was not stati stica lly signi
fican t.
Hypo thesis 3.4. The fourt h indep enden t varia ble, opini ons
about the prese nce of an in-ho use regul atory depar tment and
its
impac t on the FDA review proce ss, was evalu ated. No stati stica
lly
signi fican t

diffe rence

at

the

0.05

level

in

mean

days

to

equiv alenc e was detec ted betwe ~~ "t!la class es of agree ment, althou
gh
the vast majo rity of the respo ndent s agree d that time
to
equiv alenc e was impac ted by the prese nce of an in-ho use regul
atory
depar tment .
Hypo thesis 3. 5. The fifth indep enden t varia ble, opini ons about
regul atory consu ltant use and its impac t on time to equiv
alenc e,
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was measu red. The chi-sq uare statis tic of 11.25 was statis ticall y
signif icant at the 0.024 level of signif icance . This would seem to
sugge st that those respon dents who agreed with the tenet that
consu ltant use impac ts time to equiva lence had a statis ticall y
measu rable differ ence in mean days to equiva lence from those that
did not agree. Those respon dents who agreed h_ad lower mean days to
equiva lence than those who did not agree.
Questi on Number Four asked what combi nation of indepe ndent
variab le measu res best predic ted time to equiva lence.
Multip le regres sion predic tion conve rted beta weigh ts were
statis ticall y signif icant at the O. 05 level for opinio ns about oral
commu nicatio n with FDA and opinio ns about use of outsid e regula tory
consu ltants . Thus, as opinio ns about oral commu nicatio n with FDA
and its impac t on time to equiva lence shifte d from ·agree ing to
disagr eeing,

there

was

a

corres pondin g

increa se

in

days

to

equiva lence. And, as opinio ns about outsid e consu ltant use and its
impac t on time to equiva lence shifte d from agreei ng to disagr eeing,
there was a predic table increa se in days to equiva lence.
Questi on Number Five asked what variab les appear ed to have an
impac t on time to equiva lence as percei ved by the company
respon dent.
Eighty one percen t {n = 213) of the respon dents provid ed
additi onal entiti es which they though t impact ed the time requir ed
to get a medic al device throug h the review proces s and onto the
marke t.

Sixtee n

genera l

catego ries

~--ere

refere nced

by

the
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respon dents.

The

respon dents

noted

changi ng

regula tions

as

impac ting time to equiva lence most often (26%). The bulk of the
other comments were repres ented by the follow ing catego ries:
changi ng FDA policy , lawyer s and FDA review panel, limite d FDA
staff, and prope rly prepar ed submi ssions .

Conclu sions
This sectio n discus ses conclu sions drawn from the findin gs,
relate s them to prior resear ch, and presen ts implic ations of the
findin gs regard ing busine ss and govern ment. The resear ch addres sed
the relatio nship of federa l social regula tions and the time
requir ed to get an orthop aedic medic al device throug h the FDA
review proces s and onto the marke t for comme rcial distri butio n.
Finan cial profit and perfor mance of medic al device firms, measu red
by time to equiva lence, was gener ally impact ed by some, but not
all, compan y chara cteris tics in conjun ction with federa l social
regula tions. The degree of influe nce was temper ed by circum stance s
surrou nding the indust ry and the agency at the time of the
evalua tion. As the 1976 Amendments unfold ed in the first few yea:t·s,
both indust ry and federa l agency influe nced time to equiva lence.
This dynam ic pericd had genera l ~~siti ve and negati ve effect s on
time to equiva lence. When company chara cteris tics were examin ed
separa tely over time, specif ic positi ve and negati ve influe nces
could be percei ved.
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Of the three variab les relati ng costs and resour ce consum ption
to time to equiva lence, the numbe r oi years a compan y manuf acture
d
medic al device s tended to negati vely influe nce time to equiva lence
the greate st. The numbe r of employ ees in the organ izatio n increa sed
time to equiva lence during the early years of the amendm ent
enactm ent, but had little effec t in the later years. The number
of
employ ees in the regula tory depart ment had very little influe nce
on time to equiva lence, al though e gradua l declin e in time
to
equiva lence was seen year after year with regard to this variab le.
Of the five identi fied compan y chara cteris tics propos ed to
have an influe nce on time to equiva lence, compa nies that
manuf acture d

more

than

one

device

had

the

most

consis tent

differ ence in mean days to equiva lence over time. The type
of
device a compan y manuf acture d had little impac t on time
to
equiva lence. The presen ce of an in-hou se regula tory depart ment had
some influe nce on the mean days to equiva lence, but this was in the
years just after the enactm ent of the 1976 amendm ent. Regul atory
compl iance traini ng also had an impact on time to equiva lence, but
this was only observ ed in 1979 and 1980 when federa l guidel ines
relate d to the 1976 amendm ent were being better explic ated and
interp reted by both indust ry and agency . Use of regula tory
consul tants impac ted time to equiva lence, but only in select
ed
years. In the early years after the 1976 amendm ent enactm ent when
the

guide lines

implem ent,

were

least

unders tood

and

most

diffic ult

to

consu ltant use was highes t and seemed to have the
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great est influe nce on time to equiv alenc e. Then again in 1984,
when
new, addit ional guide lines were issue d, consu ltant use appea
red to
produ ce a diffe rence in mean days to equiv alenc e.
Of the five selec ted respo ndent s' (comp anys') attitu des about
speci fied chara cteris tics of the regul atory proce ss, the diffe
rent
class es of agree ment regar ding writt en comm unicat ion with FDA
and
use of out-o f-hou se consu ltants were most dissi milar . The data
were
gener ally suffi cient to indic ate a diffe rence in mean time
among
the diffe rent categ ories of agree ment. The respo ndent s' differ
en~
categ ories of opini on with respe ct oral comm unicat ion with
FDA,
regul atory comp liance train ing, and the exist ence of an in-ho
use
regul atory depar tment were not appar ently diffe rent as they relate
d
to mean days to equiv alenc e.
The varia bility of relat ive predi ction estim ates was great for
the twelv e combi ned indep enden t varia bles. Opini ons about use
of
outsi de consu ltants and oral comm unicat ion with FDA best predi
cted
time to equiv alenc e. A relati onsh ip was seen to exist betwe en
these
varia bles and time to equiv alenc e. Based on the class ifica
tion
system , opini ons which favor ed consu ltant use and
oral
comm unicat ion with the FDA also corres ponde d with a decre ase
in
time to equiv alenc e. Howe ver, the aggre gatio n of data as to
what
the combi ned effec t these selec ted indep enden t varia bles had
on
time to equiv alenc e was diffi cult to determ ine.
Finan cial profi ts and perfor mance are vital eleme nts in the
succe ss of the busin ess opera tion. As such, the influe nce of socia
l
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regulati on upon financia l profits and perfoJ:111anca has an ;mportan t
impact in this

area.

Conclusi ons

that there exists

a

clear

relation ship between business and governm ent, that the relation ship
sometime s benefits business operatio ns, and at other times hinders
the growth of the business , can be applied to social regulati on as
well.
While realizin g that positive , negative , and no influenc e
relation ships exist, a general statemen t on the impact of
regulati ons and company characte ristics on time to equivale nce can
be drawn from the research findings . The conclusi on is that the
general

impact

of

social

regulati on

and

selected

company

characte ristics upon time to equivale nce for small and large
orthopae dic medical device manufac turers is negative at a minor
level.
Of the many argument s in the literatu re favoring social
respons ibility, the most prevalen t was that of the long-run selfinterest of business .

This concept rational izes that society

expects business to be aware and consider the needs and goals of
society in the internal decision process if business expects to
profit in the long run. The argument is actually a sophisti cated
concept of long-run profit maximiz ation, i.e., spending money to
comply with socially imposed guidelin es will result in more profit
for business . Assuming that decrease d time to equivale nce results
in reduced complian ce costs, the literatu re by Ford (1969) and the
tentativ e results

of

prior studies

suggesti ng that

socially
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responsi ble firms :may be more profitab le were supporte d by the
present study.

Implicat ions for Business and Governm ent
The developm ent of social regulati ons in American business has
.been brought about by both external and internal events. External
causes have been largely legislat ive in nature.
Federal social regulati ons, through their impact upon profit
and performa nce of small and large firms, have impact of great
significa nce upon business and governme nt decision making and
policy formatio n in general. A managem ent philosop hy which includes
both pragmati c and idealist ic aspects often presents managem ent
with a troubleso me dilemma. On the one side, business managem ent
must pursue economic objectiv es; on the other, they must undertak e
social objectiv es. Management must attempt to resolve this dilemma.
In support of economic objectiv es, if a business firm fails
to make a profit, the firm will not survive. Should this happen,
the firm will be in no position to assume social objectiv es.
However,

this is an extremel y polar view of the dilemma.

In

reality, it is not so easy to separate economic objectiv es from
social ones.
Understa nding the particul ar impacts to be expected from
social regulati ons and how they relate to financia l profit and
performa nce is crucial to private enterpri se in their internal
decision making regardin g the policy and strategy formulat ion of
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their overa ll busine ss opera tion. A major implic ation in preced ing
studie s was the possi bility of a busine ss-gov ernme nt coalit ion. It
is essen tial for the govern ment sector to unders tand and take into
accoun t the impac t of their decisi on making and impos ition of
regula tions. To effect ively weigh costs and benef its of legisl ation
requir es knowle dge of its impac t. This has implic ations for medic al
device manuf acture rs and regula tory consu ltants . The abilit y to
determ ine

when

to

implem ent

the

exper tise

of

a

regula tory

consu ltant or expand a regula tory depart ment may have drama tic
result s on marke t emerge nce. This study sugge sts that regula tory
exper tise should be sough t within the first two years of new
regula tion enactm ent since the effect s of compl iance relate d
activ ities are most drama tic during this period . It should also be
empha sized that a regula tory consu ltant or regula tory depart ment
encom pass many indivi duals with varied exper tise. The consu ltive
team of physic ians, statis tician s, nurses , and lawyer s in conce rt
with the regula tory profes sional is needed to truly effect time to
equiva lence within the medic al device indust ry.
Attem pts to stimu late the economy throug h an increa se in
financ ial profit and perfon nance must take into accoun t curren t
polici es that work as restra ints. The study identi fied major
company chara cteris tics which intera ct with these restra ints which
impac t operat ions of orthop aedic medic al device firms.
Socia l regula tions do open up certai n oppor tunitie s of which
compa nies can take advant age. The varied impac t of social
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regulat ions in relatio n to orthopa edic medica l devices indicat es
the comple xity of the impact structu re and negates efforts to
formula te effecti ve broad-b ased regulat ory legisla tion.
Firms which fail to recogn ize the importa nce of social issues
and drag their feet on positiv e action or attemp t to side step
federa lly sanctio ned guideli nes are facing not only public and
governm ent action , but, more import antly, severe delays in enterin g
a very compet itive market. Battle lines are drawn and the challen ge
is clear. Only the future can tell what the outcome will be.
The results of this specifi c study suggest ed that medica l
device manufa cturers and possib ly other similar compan ies may
negativ ely influen ce the time require d by FDA to review a Sl0(k)
submis sion by doing the followi ng:
1)

Engage

regulat ory profess ional

consul tants when new

regulat ions which are difficu lt to interpr et by in-hous e
personn el are introdu ced or when repeate d deficie ncy
letters are returne d from FDA.
2)

Expect your regulat ory affairs consul tant to be an expert
in clinica l protoco l and designs monito ring.

3)

If trainin g provide d by sanctio ned regul~t ory bodies is
not satls£a ctory, engage consul tants to provide trainin g
to company pe~sonr iel in new develop ments in procedu res
which are sensiti ve to your medica l device.

4)

Increas e the scient ific sound.TJ.ess of the submis sions
since FDA is

continu ally increas ing its

regulat ory
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requir ement s.
5)

Commu nicate, both orally and in writin g, with FDA when
device
config uratio n or
indica tion
change s
are
introd uced.

6)

New compa nies within the medic al device indus try should
make early invest ments in regula tory exper tise since time
to equiva lence declin es with an increa se in experi ence
(i.e.,
numbe r of years manuf acturin g)
and
a
divers ificat ion of produc t (i.e., numbe r of device s
manuf acture d) •

7)

In the future , possib ly consid er indust ry self-r egula tion
with minim al FDA oversi ght.

Recom mendat ions for Future Resear ch
This was a descri ptive- compa rative study which evalua ted the
impac t of social regula tions in conjun ction with select ed company
chara cteris tics

on

orthop aedic

medic al

device

manuf acture r's

abilit y to reduce the time to reach substa ntial equiva lence with
a pre 1976 amendment medic al device as determ ined by FDA review ers.
The

study

sugges ted

severa l

areas

for

additi onal

concer ning many of the same variab les and issues .
severa l expand ed studie s were recommended as follow s:

resear ch,
There fore,

1.

Expand the curren t study to includ e a statis ticall y
signif icant number of medic al device firms other than orthop aedic.
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This recomme ndation was supporte d by this study' s question able
generali zation.
2.

Expand the current study to include other company and
agency characte ristics in the evaluati on of a medical device firm's
profitab ility. This was supporte d by the logical projecti on of this
current study.
3.

Expand the current study to include the impact of company

characte ristics and regulati ons upon other areas of profitab ility
(i.e., marketin g, manufac turing, finance, etc.) relevant to gross
income. This also appeared to be a natural projecti on of this
study's endeavo rs.
4.

Further research defining and clarifyi ng the impact,

particul arly positive contribu tions of regulati on, that is needed
to assist in effectiv e planning and decision making by bus~ness and
governm ent. This recomme ndation was guided by the need for an
alternat ive orientat ion to evaluati ng the impact of regulati ons,
since this study was basicall y negative in perspect ive.
5.

Further research should be done using a larger sample.

with any experime ntal design and analysis , more confiden t
inferenc es can be made and conclusi ons drawn when the study sample

As

more approxim ates the study populati on.
6.

Expand the study to represen t both large and small firms

equally and analyzed separate ly. This also would. further generali ze
the study results.
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7.

Devel op a study to inclu de only Class III devic es since
there are more profi tabil ity measu res assoc iated with this
mora
risk relate d devic e.
8.
betwe en

Devel op a study which clear ly confi rms the conne ction
socia l regul ation s and profi t and perfo rmanc e. This

recom menda tion was based on the l~ter ature suppo rted need for
such
analy sie.
9.

Devel op a study to educa te medic al devic e manu factur ers
about the most effic ient and cost effec tive paths to regul
atory
comp liance .

This recoJIDDendation was appar ent in view of this
study 's findin g that reg-~ latozy train ing seeme d have littl e
impac t

on time to equiv alenc e.
10.

Desig n a study to ds~el op the relia bilit y and valid ity
of the measu remen t in.stru ment. This r~~om menda tion was based
on the
need for a more ac~ur ate and stand ardiz ed data colle ction vehic
le.
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APPENDIX A

Dir ecto r, Reg ulat ory Dep artm ent
P.O . :Sox 988
O. S. Highway 30 Eas t
Warsaw, IN 46S 80
Dea r Dir ecto r,

In con jun ctio n wit h the Uni ver
of San Die go, I am con duc ting
rese arc h in the fiel d of reg ulasity
tory
Par t of the ini tia l stag es of theaff air s and med ical dev ices .
rese arc h req uire s a pil ot
stud y. Its pur pos e is to ass ess the via
bil ity and fea sib ilit y of
the pro pos ed stud y. One of the mai n task
asse ssm ent of the dat a col lec tion form s of thi s pil ot is the
or que stio nna ire.
Ple ase find enc lose d a cop y of the que
stio nna ire tha t wil l be
mai led to app rox ima tely 250 reg
ula
tory
aff
airs man age rs suc h as
you rse lf. The se man age rs wil l be from
thro
u,qh
o\tt ~·!e U.S . Alo ng
wit h the que stio nna ire, the reg ula tory
aff airs man age r wil l
rec eiv e a cov er let ter exp lain ing
the rese arc h pro jec t. You hav e
a cop y of thi s as wel l.
·
I ful ly app rec iate you r ver y bus y sch edu
le, but you r ass ista nce
is nee ded in the val ida tion pro ces s of
thi
s que stio nna ire. Would
you take 20-3 0 min utes to revi ew the
enc
lose
d cov er let ter and
que stio nna ire? Some of the
s whi ch I wou ld like you to
add ress are : l) Is the que stioarea
nna ire rea list ic? 2) Wil l man age rs
fil l it out ? 3) Do the que stio ns add
the issu e of com plia nce
and the tim e nee ded to get a dev ice ress
thro
ugh
the SlO (k) pro ces s?
4) Are the re que stio ns whi ch mig ht
com
prom
ise the company? 5)
Does the cov er let ter invo ke a fee ling
of
coo per atio n whi ch
wou ld help sec ure the par tici pat ion of
the man age r in the stud y?
Your comments are ess ent ial to the
suc ces s of thi s pro jec t.
Ple ase fee l free to wri te dir
ect
ly
on the cov er let ter and
que stio nna ire. Once fini she d, ple ase retu
sel f add ress ed Fed era l Exp ress ove rnig rn the docume,1ts in the
ht env elop incl ude d her e.
A pre lim ina ry pul: )lis hing agre
eme nt has bee n reac hed wit h a
jou rna l inte res ted in the res ults
thi s stud y. Your comments
and con trib utio ns wil l make thiof
s
pro jec t tha t much mor e
rele van t.
Thaz,Jc you for you r tim e and coo per atio
n. Hop efu lly, our ef fori :s
may pro duc e a doc ume nt whi ch may
fac
ilit
ate the SlO (k) pro ces s
and sav e med ical dev ice man ufa ctu:
ers money and reso urc es.
Sin cer ely ,
Joh n J. Car low
Dir ecto r, Cli nic al Sta tist ics
JJC /md g
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APPENDIX B

Sup erv isor - Cli nic al/R egu lato ry Aff air
3M Company
3M Cen ter 270 -SN -05
St. Pau l, MN 551 44
:,ea r Ms. Dan iels on,
Res earc h is bei ng con duc ted en
imp act of gov ernm ent reg ula tion s
upo n the tim e req uire d to get anthe
orth
opa edi c med ical dev ice thro ugh
the FDA rev iew pro ces s and ont o the mar
thro ugh pub lica tion of the SlOlk) Reg ket. Your firm was sele cte d
cri ter ia bec aus e you r co~ pan yha s had iste r. You met the sele ctio n
at lea st one pro duc t app rov ed
th.r oug h the SlO (k) pro ces~ betw een the
yea rs 197 7-19 87 •
The key rol e you hav e in you r fixm 's
suc ces s makes you r view and
,:ou nse l of extr eme val ue. Wou
ld
ycu
rese arc h by com plet ing the enc lose d q,~ple ase con trib ute to thi s
esti onn aire .
The que stio nna ire is des ign ed to obt ain
spe cifi c info rma tion abo ut
you r company. In add itio n, you
r
opi
nio
n
reg ula tion upo n you r firm 's abi lity on the imp act of fed era l
thro ugh the prem arke t not ific atio n pro to suc ces sfu lly pro gre ss
ces s is also bei ng req ues ted .
Rec ogn izin g you r dem and ing sch
le, the form was des ign ed to be
com plet ed in a minimum of edu
tim
If, aft er com plet ing the
que stio nna ire, you des ire a summarye. cop
ple ase ind ica te so on the form . Res ults y of the rese arc h res ults ,
are exp ecte d to be mai led
in !'.ay, 199 0.

.

If you so cho ose , you do not hav e to
par tici pat e in thi s rese arc h
pro jec t. How ever , if you cho ose
to
par
que stio nna ire, you are not req uire d to tici pat e by com plet ing the
may be com prom isin g to you or you r com ans wer que stio ns you fee l
pan y.
The info rma tion you con trib
to th.i s rese arc h wil l rem ain
con fide ntia l and be use d onl y ute
to sup por t thi s stud y.
It is ess ent ial tha t you r resp ons e be
rec eiv ed by Sep tem ber, 198 9.
You r con trib utio n, by com plet ing
the
enc
lose d que stio nna ire, wil l
add .immensely to the kno wle dge in thi
s are a.
Th~&k you for you r tim e and int ere st.
Sin cer ely 1

J'O!"u"l

J. Car low ,

Res earc her
Enc losu res
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APPENDIX C
SURVEY QUESTIONNAIRE

l.O

Ple ase ind ica te the yeu you r ccmpan
y sta rte d ma nu: act urin g
me dic al dev ice s?

2.0

Ple ase sup ply the foll ow ing
rma tion as it rel ate s to the
yea rly int en- als in the lef t info
colu
If you r company was not
ma nuf act urin g me dic al dev ice s durmn.
ing
cer
tai n yea :ly int erv als ,
lea ve tha t sec tio n inc om ple te.
Did you r Dep t.
Use out sid e
Reg ula tory
Con sul tan ts

Number of
Em ploy ees J.n
Org an.i zati o n
197 7

_Y es

_N o

197 8

__Yes

_N o

197 9

__Yes

_N o

198 0

_Y es

_N o

198 1

__Yes

__No

198 2

_Y es

__No

1983

__Yes

_N o

1984

-

xes

_N o

_Y es

_N o

_Y es

_N o

_Y e~

_N o

Tfi s
1Tii"
1987
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APPEEDIX C ( con tinu ed)

3.0

Ple ase sup ply the foll owi ng info ma
tion as it rela tes to the
yea rly inte rva l in the lef t colu mn.

Wer e you Man ufac turi ng
Mor e tha n One Dev ice

Did you r Dep artm ent
Rec eive Reg ulat ory
Tra inin g of any lind

1977 _Y es _N o

_Y es

ma _Y es

_N o

_N o

_Y e3

_N o

1979 _Y es

_N o

mo

_Y es

_N o

_N o

_Y es

__No

_Y es

_N o

__Yes

Tff i _Y es _N o
Tm" _Y es __No
mJ _Y es __No

_Y es

__No

__Yes

_N o

l98 4 __Yes

__No

_Y es

_N o

1985 _Y es

_N o

_Y es

__No

198 6 __Yes

_N o

_Y es

__No

198 7 _Y es

__No

_Y es

_N o

4.0 In you : opi nio n, are pro duc tion
cos ts infl uen ced by the tim e
req ui.r ed to get a dev ice

thro ugh the rev iew proc etss and ont o
the ma: ket. _Y es _N o. If y<!s
, ple ase exp lain .
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APPENDIX C (co ntin ued )

Ple ase ind ica te you r PER.CBPTION of the
foll owi ng eve nts or situ atio ns hav e PREkin d of in£ luen ce the
nee ded to get a pro duc t th:o ugh the FOASENTLY on the tim e tha t is
the mar ket. Ci: cle the app rop riat e cate rev iew pro ces s and to
gor y tha t des crib es you r
per cep tion for que stio rui 4 thro ugh 8
belo w.
4.0

Wr itte n Com mun icat ion bey ond the sub mis
sion wit h the FDA res ults
in dec reas ed tim e to get a pro duc
t
thro
ugh
the FDA rev iew pro ces s
and on the mar ket.
Stro ngl y
Agr ee

Agr ee

No
Opi nion

D.i.sagree

Stro ngl y
Dis agr ee

S.O

Oral Com mun icat ion wit h the FDA res ult s in dec
reas ed tim e
pro duc t th.r oug h the F0A rev iew
pro ces s and on ·ehe mar ket. to get a
Stro ngl y
Agr ee
No
Dis agre e
St:- ong ly
Agr ee
Opi nion
Dis agr ee

6. 0

Reg ulat orv Af f ai:::-s Tra inin g res ults in
d.ec reas ed tim e to get ¼
pro duc t th.r oug h the FDA rev iew pro
ces s and on the mar ket.
Stro ngl y
Agr ee
No
Dis agr ee
Stro ngl y
Agr ee
Opir,.ion
Dis agr ee

7.0

An In-h ous e Reg ulat o.rv Aff airs Deo artm
tiln e to get a pro duc t 1:1lrough the ?DA ent res ults in dec :eas ed
revi ew pro ces s and on the
mar ket.

Stro ::ig ly
Agr ee
8.0

No
Opi nion

Dis agr ee

Stro ngl y
Dis agr ee

use of out sid e Reg µlat orv A,;f
Con sult ants res ults in dec reas ed
tim e to get a pro duc t thro ugh airs
the
FDA
rev iew pro ces s and on the
mar ket.

Stro ngl y
Agr ee

~.0

Agr ee

Agr ee

No
Opi nio c

Dis agr ee

Stro ngl y
Dis agr ee

In you r opi nio n, are ths re oth er thin gs
wni ch imp act the tim e
get a pro duc t thro ugh t~e rsv iew
pro ces s and ont o the mar ket? to

If you wan t the res ults of th.i s r9s ear
ch forw arde d to you , ple
ind ica te l)y che ckin q the app rop
riat e cat ego :y. _Y es _N o ase
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APPENDIX D
Snmmary of Res ear ch
oth ese s Reg ard ing
the Rel atio nsh ip Bet wee n OrgHyp
ani zat ion al Ch ara cte rist ics
and Time to Est abl ish ed Equ iva len ce
~IO NS HI P

Hyp oth esis
Number
1.1

1.2

l.3

Dep end ent
Va :iab le

Ind e'Ce nde nt
Var iab le

Exp ecte d Dir ect ion
of the Rel atio nsn ip

Time (da ys) to
Equ iva len ce.

Number of Yea.rs
ma nuf act urin g
Me dica l Dev ices

Neg ativ e

Till:e (da ys} to
Equ iva len ce.

NUlnber of
Em ploy ees in
v;..;ci.g-cm.ization

Neg ati, re

Time (d.ays) to
Equ iva len ce.

NUlnber of
E:.n.ployees in
Reg ula tory
Depa.rt:11en1:

Neg ativ e
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APPENDIX E

Summary of Rese arch Hyp othe ses Reg a:din g
The Diff eren ce Bet -~~ Company Cha rtac
teri stic s
and. Tim ely Com plian ce
COMPARISON

Hyp othe sis
Numl:)er

Dep ende nt
Var iabl e

Inde pend ent
Va:i a.ble

Sign ifica nce
Leve l a a.OS

Time (day s) to
Equ ival ence .

Type of
Dev ice
Man ufac tured .

Sign ifica nce
Leve l a a.OS

Time (day s) to
Equ ival ence .

In-a :ous e
Reg ulat ory
Dep artm ent

Sign ifica nce
Leve l = a. 05

Time (d.ays) to
Equ ival ence .

Reg ulat ory
Com plian ce
Trai ning

Sign ifica nce
Lev el= a.as

Time ( ciays) to
Equ ival ence .

Numl:)er of
Dev ices
Man ufac tured .

Sign ifica nce
Leve l :a a.as

Time ( ciays) to

Use of Out side
Reg ulat ory
Con sult ants

Sign ifica nce
Lev el= a.as

2.l

2.2

2.3

2.4

2.5

:6:q-.:ivalc :nce •

I

Page 151

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX 'Z

Summary of Research H7POtheses Regarding
Difference s in Top Executives Perceived Influences
on Timely Ccmpliance and Time to Equivalenc e

COMPARISON

Bn,othe~is
Nmnber
3.l

3.2

3.3

3.4

Dependen-e
Va.:iable
Time (days) to
Equivalenc e.

Time (days) to
Equivalenc e.

Significan ce
Level

FDA

Written
Communica tion

Significan ce
Level= a.as

FDA

Cral
Communica tion

Significan ce
Level 2 0.05

Time (days) to
E;_1livalence.

OSMA/Reg ulatory
T:raining

Time (days) to
Equivalenc e.

In-Bouse
Regulatory
Departmen t

Significan ce
Level 2 a.as

Time (days) to
Equivalenc e.

Outside
Regulatory
Consultan ts

Significan ce
Level• 0.05

I
3.5

Independen t
Variable

Significan ce
Level= a.as
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